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Acinetobacter baumannii is an important opportunistic pathogen of hospital acquired 
infection, particularly in intensive care units. The emergence and rapid spread of multidrug-
resistant A. baumannii strains has become a major health threat worldwide which severely limits 
the treatment options for this pathogen. This work investigated global mechanisms of antibiotic 
resistance and virulence of the problematic pathogen A. baumannii, in particular those mediated 
by two component regulatory systems (TCSs), that typically consist of a membrane bound sensor 
kinase and a cognate response regulator. Bacterial TCSs play an important role in the regulation 
of adaptation to different environmental conditions. Five TCSs in A. baumannii have been 
characterized; however, there are a number of putative two component systems encoded in the 
genome of A. baumannii that await detailed characterization. Differential expressions of six 
different TCSs was observed in two clinical isolates of A. baumannii AB030 and AB031, and 
whole-genome sequencing of both clinical isolates was performed. Data obtained from the 
comparative whole-genome analysis revealed the presence of an insertion element in the orphan 
TCSs response regulator A1S_2006 in AB030, mutation in the promoter region and an 1189 
DNA insertion element were present in AdeRS system in AB031. The whole-genome 
sequencing analysis of TCSs operons in AB030 and AB031 also identified sequence 
polymorphisms that could alter the activities of these TCSs in AB030 and AB031. Finally, we 
identified A1S_3229_30 an excellent candidate that may act as global regulator of antibiotic and 
virulence in A. baumannii. The sequence of A1S_3229_30 was highly conserved among the 
wild-type ATCC17978, AB030 and AB031, and showed 73% identity to the amgRS operon that 
encodes for the well characterized AmgRS system that confer resistance to aminoglycoside 
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1.1 Acinetobacter baumannii 
 
Acinetobacter baumannii is a Gram-negative coccobacilli and that is being increasingly 
recognized as an important pathogen that causes severe infections in hospitalized patients 
(Cisneros et al., 1996). The genus Acinetobacter is diverse, and bacteria belonging to this genus 
can be found in soil, surface water, vegetables, animals, and humans. The presence of 
Acinetobacter species on healthy individuals’ skin was reported, and majority of the skin isolates 
belonged to A. lwoffii, A. johnsonii and A. junii, whereas A. baumannii skin carriage is rare in 
healthy individuals (Dijkshoon et al., 2007; Zordan S et al., 2011). The natural reservoirs of A. 
baumannii remain unclear, and this species has been isolated mainly from the hospital 
environment.  
1.2 Acinetobacter baumannii clinical relevance 
 
A. baumannii has been implicated in a variety of nosocomial infections, including 
bacteremia, urinary tract infection, and secondary meningitis as well as ventilator-associated 
pneumonia in patients confined to hospital intensive care units (ICUs) (Peleg et al., 2008; 
Michalopoulos and Falagas, 2010). Mortality rate of 26% -70% has been reported for A. 
baumannii infection in ICUs (Alsan and Klompas, 2010). In the United States, occurrence of 
multi-drug resistant (MDR) A. baumannii has increased from 6.7% in 1993 to 29.9% in 2004, 
which is twice the rate of MDR emergence of any other ICU-relevant Gram-negative bacillus 
(Maragakis and Perl, 2008).  
During the conflicts in Iraq and Afghanistan, A. baumannii infections were reported 
among severely injured returning Canadian and American soldiers (Tien et al., 2007). It is 
hypothesized that this has played a major role in triggering an increase of the occurrence of A. 
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baumannii infections among civilian hospitalized patients in North America (Hujer et al., 2006). 
The recent Centers for Disease Control and Prevention (CDC) 2013 report has highlighted A. 
baumannii as a serious level of threat to human health. The report has also documented that A. 
baumannii causes 12,000 infections per year in the US, of which 7,300 are multidrug resistant, 
and it is responsible for 500 deaths (Centers for Disease Control and Prevention (CDC), 2013).  
1.3 Antimicrobial resistance in Acinetobacter baumannii 
 
A major factor that contributes to the pathogenesis of A. baumannii is its resistance to a 
number of antibiotics commonly used to treat infections caused by Gram-negative bacteria 
(Gaynes and Edwards, 2005). It displays a remarkable capacity to develop clinical resistance to 
broad-spectrum β-lactams, aminoglycosides, fluoroquinolones, tetracyclines, and in recent years, 
to carbapenems, which have been the most powerful agents against infection caused by 
multidrug resistance since the late 1980s (Vaara et al., 2010). Pandrug resistance of A. 
baumannii has left tigecycline (one of the most recent antibiotics approved for clinical use) and 
polymyxin B (an older antibiotic that is known for its nephrotoxicity) as the drugs of last resort 
(Afzal-Shah et al., 2001; Valenzuela et al., 2007; Mark et al., 2009). 
However, with recent reports of A. baumannii resistance to polymyxins (Ko et al., 2007) 
and tigecycline (Valencia et al., 2009) it is feared that this organism may become resistant to 
every single antimicrobial agent currently available (Maragakis and Perl, 2008). 
i. Mechanisms 
 
A. baumannii has become resistant to most of the antibiotics available. Drug resistance in 
A. baumannii can either result from intrinsic mechanisms present in Gram-negative species, or 
through acquisition of novel genetic information through horizontal gene transfer (Magnet et al., 
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2001; Mammeri et al., 2003). Antibiotic resistance mechanisms for A. baumannii can be 
classified into three categories (Piddock, 2006). The first category is the production of 
antimicrobial-inactivating enzymes (β-lactamases, cephalosporinases, and carbapenemases) that 
hydrolyze and confer resistance to penicillins, cephalosporins, and carbapenems (Drawz et al., 
2010). The most common mechanism of β-lactam resistance in A. baumannii is inactivation of 
the drug by β-lactamase enzymes, which can be either chromosomally- or plasmid-encoded 
(Roca et al., 2012). The second category involves modification of membrane permeability or 
increased efflux (Limansky et al., 2002); however, little is known about the permeability of the 
outer membrane in A. baumannii or its outer membrane porins (Vila et al., 2007). The third 
category of resistance mechanisms involves alterations that change antibiotics’ targets or 
bacterial cell functions, this type of mechanism in A. baumannii confer resistance to quinolone 
agents by mutations in the bacterial targets gyrA and parC topoisomerase enzymes (Maragakis 
and Perl, 2008). Overall, A. baumannii can express all mechanisms of resistance as described 
above such as enzymatic inactivation of the antibiotic, mutation(s) in the structural or regulatory 
genes of the target protein, decreased permeability of the outer membrane transport of the agent 
out of the cell by efflux (Damier-Piolle et al., 2008; Roca et al., 2011). 
However, recent studies have highlighted that presence of the energy-mediated efflux of 
antibiotics plays a crucial role in the intrinsic resistance of Gram-negative species (Li et al., 
2002; Lin et al., 2009). A. baumannii possesses efflux pumps that are capable of actively 
removing a broad range of antimicrobial agents from the bacterial cell, and responsible for 





ii. RND efflux pumps 
 
Multidrug efflux pumps belonging to the Resistance-Nodulation cell-Division (RND) 
family have been identified as the most common and important efflux system among MDR 
Gram-negative bacteria (Morita et al., 2012). RND pumps are comprised of an outer membrane 
protein (OMP), an inner membrane RND transporter and a membrane fusion protein (MFP) that 
links OMP and RND components together. RND pumps are driven by a substrate/H+ antiport 
mechanism and have been linked not only to efflux of antibiotics, but also broad range of 
structurally unrelated molecules/ions, such as: biocides, heavy metals, dyes, organic solvents, 
detergents, metabolic inhibitors, bile salts and homoserine lactones, involved in quorum sensing 
(Poole, 2004). To date, three RND-efflux pumps have been described in A. baumannii AdeABC 
Magnet S et al., 2001) AdeIJK (Damier-Piolle et al., 2008) and AdeFGH (Coyne et al., 2010). 
These three efflux pumps have shown capability to confer resistance to a variety of antibiotic 




The first line of defense for Gram-negative bacteria against toxic compounds is the outer 
membrane. This barrier is resistant to large, charged molecules. Permeability of the outer 
membrane largely controlled by porins, which are water-filled open channels that span the outer 
membrane and allow the passive penetration of hydrophilic molecules (Galdiero et al., 2012). 
Outer membrane proteins (OMPs), such as porins and efflux pumps, play a fundamental role in 
the organism pathogenicity and its antibiotic resistance. It has been reported the role of altered 
porins expression in antibiotic resistance to a number of hydrophilic antibiotics like β-lactams 
6 
 
and carbapenems. To date, three porins have been identified in A. baumannii CarO (Catel-
Ferreira et al., 2011), OprD (Catel-Ferreira et al., 2011), and 33kDa porin (Clark, 1996). These 
porins showed association to carbapenems resistance in A. baumannii (Mussi et al., 2005; Del 
Mar Tomas et al., 2005). 
1.4 Virulence of Acinetobacter baumannii  
 
In the past, A. baumannii was considered to be an organism of low virulence, but the 
occurrence of several infections, such as community-acquired Acinetobacter pneumonia 
indicates that this organism displays high pathogenicity and causes invasive disease. The 
treatment of A. baumannii infections is complicated by ignorance of the molecular and cellular 
mechanisms of pathogenesis in the host. Much still needs to be discovered about A. baumannii 
virulence factors that are involved in producing biofilms, killing the host cells, and causing 
infections (Gaddy and Actis, 2009). 
Several bacterial virulence factors are required for A. baumannii to colonize and infect 
the host. However, very little information is known about these virulence factors in A. 
baumannii. There have been recent studies characterizing some virulence factors, such as 
phospholipase D and phospholipase C , biofilm formation, outer membrane protein A (OmpA), 
penicillin-binding protein 7/8 (PBP-7/8), and ferric iron chelators (siderophores) (Roca et al., 
2012).  
The surface protein OmpA is involved in the adherence to and invasion of epithelial cells 
and induces apoptosis in the early stages of A. baumannii infection (McConnell et al., 2011), 
while the hydrolytic enzymes PLD and PLC play a role in the organism ability to survive in the 
human serum, epithelial cell invasion, and enhance cytotoxicity on epithelial cells (Antunes et 
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al., 2011). During colonization, A. baumannii forms biofilm, a highly structured microbial 
community, which results in adhesion to host cells, survival on other surfaces, and resistance to 
antimicrobial agents (Gaddy and Actis, 2009). Penicillin-binding protein 7/8 (PBP-7/8) 
contribute in the growth and survival of A. baumannii in human ascites, and showed indirect 
participation in human serum resistance (Cayo et al., 2011). The ability of A. baumannii to 
produce siderophores helps the organism survive and multiply under iron-limiting environments 
in the host (Dorsey et al., 2003). 
1.5 Two component systems in bacteria 
 
Rapid adaptation to environmental challenge is essential for bacterial survival. To adapt to 
changes in their surroundings, bacteria mainly use the two component systems (TCSs). Such 
systems are signal transduction pathways in bacteria (as well as certain archaea, protozoa, plants, 
and fungi) and respond to change in environmental conditions (Mitrophanov and Groisman, 
2008). The prototypical TCSs consist of a membrane bound sensor kinase, and a response 
regulator that is present in the cytoplasm. The role of the sensor kinase is to direct a 
phosphorylation of its cognate response regulator in response to an extracellular environmental 
signal, this phosphorylation activates the response regulator to regulate the expression of a large 




Figure 1. A schematic representation of common two component system in bacteria. The 
common TCSs are usually composed of a sensor kinase located in the outer membrane, which is 
able to detect one or several environmental stimuli, and a response regulator in the cytoplasm, 
which is phosphorylated by the sensor kinase and which, in turn, activates the expression of 











Different environmental conditions detected by TCSs in bacteria are well characterized. 
These signals are thought to be chemical and physical parameters such as temperature, pH, 
oxygen pressure, osmolality, autoinducer compounds and antibiotics (Krell et al., 2010). These 
TCSs can be characterized into several groups based on their actions: control of metabolism, 
respiration, influx and efflux, chemotaxis, and stress response (Mitrophanov and Groisman, 
2008). Moreover, the role of the TCSs in the pathogenicity of bacteria has been reported in 
different microorganisms.  
i. Role of TCSs in antibiotic resistance and virulence 
 
Different TCSs have been reported to play a role in the regulation of antibiotics resistance 
and virulence in several organisms. For example, PhoPQ in Salmonellae regulates the protein 
and lipid content of the bacterial envelope that modifies the inner and outer membrane results in 
increased resistance to cationic antimicrobial peptides and production of some virulence factors 
associated with secretion systems (Dalebroux and Miller, 2013). In another study, Manoil et al., 
(2009) identified AmgRS system in the pathogen Pseudomonas aeruginosa that appears to 
control a conserved membrane stress response. Inactivation of amgRS has led to increase 
aminoglycoside efficacy in clinical situations in which antibiotic treatment often fails. 
Interestingly, the amgRS mutant was considerably less virulent than its parent in acute murine 
infections in the absence of antibiotics, which suggests that AmgRS response is required for full 
virulence, and its inhibition is expected to provide the dual benefit of compromising infection 
directly as well as enhancing antibiotic sensitivity (Lee et al., 2009). These findings strongly 
highlight the control of TCSs in regulating virulence and drug resistance in pathogenic 
organisms. Thus, TCSs seem to be a good therapeutic target for the discovery of new treatment 
options against multidrug resistant microorganisms’ infections.  
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ii. TCSs as new targets options for treatment  
 
The rise in infections caused by MDR pathogens is becoming a global health problem, 
this creates a need for development of new antibiotics to treat these deadly infections. Over the 
last few decades, the introduction of new antibiotics is not keeping pace with the rapid evolution 
of resistance to almost all clinically available drugs, this created a need to look for alternative 
strategies to overcome the MDR problem. Inhibiting TCSs is a promising strategy to identify 
new novel antimicrobial agents that inhibit microbial virulence without inhibiting growth, which 
leads to less pressure for the generation of resistance (Gotoh et al., 2010).  
Rasko et al., (2008) have reported a small molecule that inhibits the histidine sensor 
kinase QseC in Salmonella Typhimurium by inhibiting the signals to the sensor kinase, 
preventing its phosphorylation. This compound inhibits virulence of several pathogens in animal 
studies without killing the bacterial cells. WalK/WalR is another novel target for the 
development of antibacterial agents against multidrug resistant bacteria including methicillin-
resistant S. aureus. Singermycin B was discovered as a new antibiotics that targets the 
dimerization domain of WalR and inhibits bacterial growth (Watanabe et al., 2012). In another 
study, a small molecule has been used as an adjuvant that suppresses the colistin resistance by 
interfering with the expression of the TCSs pmrAB in A. baumannii and Klebsiella pneumonia 
(Harris et al., 2013).  
In summary, TCSs are potentially a great target for the development of new therapeutic 
options against MDR bacterial infections. Since TCSs are major players of the regulation of 
virulence and antibiotics resistance, better understanding of the mechanisms of these TCSs in 
multidrug resistance and virulence the emerging MDR pathogens is required.  
12 
 
1.6 Two component systems in Acinetobacter baumannii 
 
Around nineteen different TCSs have been identified in A. baumannii, most of these were 
present in sequenced clinical strains (A. baumannii AB0057, AYE, ACICU, AB307-0294, 
AB900, SDF, and ADP1). Fifteen of these are conserved in all sequenced strains including the 
type strain A. baumannii ATCC17978 (Adams et al., 2008). Of these, five TCSs have been 
characterized so far, PmrAB, BfmRS, AdeRS, BaeSR and GacSA.  
i. PmrAB 
 
Colistin and polymyxins are antibiotics that were commonly used in the 1960s-1970s but 
were abandoned because of reports of toxicity. Outbreaks of polymyxin-resistant A. baumannii 
have been reported (Fernandez-Reyes et al., 2009), and resistance to these drugs is mediated by 
replacement of Lipid A with aminoarabinose which is controlled by pmrC. The TCSs PmrAB 
plays a role in the expression of genes implicated in lipid A modification and thus influence 
sensitivity to colistin. Knockout of the pmrB gene in two clinical isolates has led to a decrease in 
the polymyxin B and colistin susceptibility, these findings suggested that alterations in the 
sequence of the PmrCAB are responsible for resistance to polymyxins and colistin in A. 
baumannii (Arroyo et al., 2011; Beceiro et al., 2011). 
ii. BfmRS 
 
It has been demonstrated that A. baumannii has the ability to form pili to adhere and form 
biofilm which depends on the expression of the csuE gene. Inactivation of the csuE disrupted pili 
production and biofilm formation suggesting that CsuA/BABCDE-mediated pili play an 
important role in the biofilm formation. The expression of the csuE gene is controlled by a two 
component system consisting of a sensor kinase encoded by bfmS and a response regulator 
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encoded by bfmR. Inactivation of the sensor kinase does not abolish the biofilm formation; 
however, inactivation of the response regulator bfmR results in a loss of the expression of the csu 
operon and, therefore, abolition of the pili production and biofilm formation. These findings 
suggest that the expression of a responsible gene for biofilm formation in A. baumannii is 
controlled by the two component system BfmRS (Tomaras et al., 2008). 
iii. AdeRS 
 
The expression of AdeABC efflux pump is tightly regulated by the two-component 
system that contains a sensor kinase (SK) adeS and a response regulator (RR) adeR, encoded by 
the adeRS operon. The adeRS operon is located at the upstream of adeABC operon and is 
transcribed in the opposite direction contributing to resistance to aminoglycosides, tetracycline, 
erythromycin, chloramphenicol, trimethoprim, and fluoroquinolones (Sun et al., 2012). 
Disruption of adeR and adeS genes by insertional mutagenesis resulted in increased 
susceptibility of the mutant strains of A. baumannii to aminoglycosides and other substrates of 
the pump (Marchand et al., 2004). Two component systems have been reported to control the 
expression of drug efflux transporters in other bacterial species, but are considered to be an 
uncommon mode of regulation of efflux pumps. 
iv. BaeSR  
 
In Escherichia coli, BaeSR system is known to upregulate the expression of efflux pumps 
in response to specific envelope damaging agents (Leblanc et al., 2011). A recent study done by 
Lin et al., (2013) have identified BaeSR system in A. baumannii, and showed that a baeSR 
deletion mutant was susceptible to tigecycline. The study also hypothesized that this system 
could play a role in the regulation of the RND efflux pump adeABC, which suggests that there is 
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The sensor kinase gacS deletion mutant was analyzed using transcriptional profiling and 
functional assays. GacS was shown to regulate key virulence factors including pili production, 
biofilms and motility. Transcriptomic profiling showed that 674 genes were affected by the 
deletion of gacS, and based on in slico analysis an orphan response regulator was identified and 
predicted as GacS response regulator GacA. The TCSs GacSA is thought to be the first 
characterized global virulence regulator in A. baumannii (Cerqueira et al., 2013).  
1.7 Knowledge gaps  
 
TCSs are absent in mammalian cells which emphasizes the need for inhibitors of such 
systems that are considered a great strategy to overcome MDR pathogens infections. Relatively, 
few virulence factor have been characterized in A. baumannii, and much needs to be explored 
about the global mechanisms that control antibiotic resistance regulation and production of 
virulence factors of A. baumannii. The knowledge obtained during this study will contribute to 
the understanding of the action of TCSs in A. baumannii, as well as their participation in the 
global mechanisms used by this microorganism to overcome adverse conditions in clinical 
settings. Finally, this research will supply additional information to create a better understanding 





1.8 Hypothesis  
 
Two component systems act as global regulators of antibiotic resistance and virulence and 
their better characterization will lead to novel therapeutic options for treating infections caused 
by MDR A. baumannii. 
 
Therefore, the objectives of this thesis are:  
 
A. Cloning of two component systems-encoding operons of A. baumannii 
 
B. Creation of gene knockouts for two component systems  
 




















2.1 Bacterial strains, plasmids and oligonucleotides   
 
Bacterial strains, plasmids, and oligonucleotides used in this study are listed in Tables 
2.1, 2.2, and 2.3, respectively. The clinical isolates of Acinetobacter baumannii were collected 
from Canadian Hospitals provided by Dr. George Zhanel, University of Manitoba, Canada 
(Fernando et al., 2013). A. baumannii ATCC17978 was used as the wild-type strain.  
2.2 Growth and culture conditions  
 
Bacteria were routinely cultured in lysogeny broth (LB) at 37 °C (Biobasic Inc., 
Markham, ON, Canada) and supplemented with the appropriate antibiotic where necessary to 
maintain plasmids. The following concentrations: 100 µg/mL ampicillin (Bioshop Canada Inc., 
Burlington, ON., Canada) and 30 µg/mL gentamicin (Bioshop Canada Inc., Burlington, ON., 
Canada), 50 µg/mL trimethoprim (Bioshop Canada Inc., Burlington, ON., Canada), 15 µg/mL 
streptomycin (Sigma Aldrich Co., St Louis, MO, USA), and 10 µg/mL tetracycline (Bioshop 
Canada Inc., Burlington, ON., Canada) for selection of E. coli strains. Concentrations of 
antibiotics used for A. baumannii are 200 µg/mL carbenicillin (Bioshop Canada Inc., Burlington, 
ON, Canada), 50 µg/mL gentamicin (Bioshop Canada Inc., Burlington, ON, Canada). 
2.3 DNA manipulation  
 
i. DNA extraction 
 
Genomic DNA was extracted using the DNeasy Kit from Qiagen® (Qiagen, Mississauga, 
ON, Canada) according to manufacturer’s instructions. Briefly, cells from 1.5 mL of overnight 
culture were harvested and directly lysed by incubating with proteinase K at 56˚C for 10 min, 
96-100% ethanol was added and the mix was transferred to a silica membrane column. The 
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column was washed twice with ethanol solution and the DNA was extracted from the column 
using 100 to 200 µL of elution buffer. Plasmid DNA was extracted using EZ-10 Spin Column 
Plasmid DNA Miniprep Kit from BioBasic (BioBasic Inc., Markham, ON, Canada) by following 
the manufacturer’s instructions. The DNA concentration was measured using the NanoDrop Lite 
Spectrophotometer (Thermo Fisher Scientific In, Mississauga, ON, Canada) and all samples 
were stored either at 4°C or -20°C.  
ii. Extraction of DNA fragments from agarose gels 
 
GeneJET Gel Extraction Kit from Thermo Scientific (Thermo Fisher Scientific In, 
Mississauga, ON, Canada) was used to purify DNA fragments from 0.8% agarose gels (Biobasic 
Inc., Markham, ON, Canada) following manufacturer’s instructions. Briefly, a gel containing 
DNA was excised and dissolved in Binding buffer by incubating at 56°C for 10 minutes. The 
mixture was transferred to a silica membrane column and washed once with ethanol solution and 
the DNA was extracted from column with adding 20 to 30 µl of elution buffer. DNA 
concentration was measured using the NanoDrop Lite Spectrophotometer (Thermo Fisher 
Scientific In, Mississauga, ON, Canada) and samples were stored at 4°C. 
iii. DNA restriction digestion, ligation, and polishing 
 
Restriction enzymes were used to confirm the identity of plasmids, as well as for cloning 
DNA. Enzymes were used following the manufacturer’s instructions (New England Biolabs Ltd., 
Pickering, ON, Canada). Ligations were performed using T4 DNA ligase (Invitrogen Inc., 
Burlington, ON, Canada) or from (Promega, Madison, WI, USA) using varying molar ratios of 
the insert and vector. The ligation mixtures were incubated at 14°C overnight. DNA fragments 
were polished with a T4 DNA polymerase (NEB England Biolabs Ltd., Pickering, ON, Canada) 
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at 12°C for 20 minutes and the enzyme was heat inactivated at 75°C for 15 minutes to create a 
blunt-ended product for ligation. 
iv. Construction of the suicide vector pPLS103 
 
The suicide plasmid pKNG101 (Kaniga et al., 1991) was digested with the restriction 
enzymes SacI and NotI (NEB England Biolabs Ltd., Pickering, ON, Canada) to remove the 1460 
bp selection marker strAB encoding for streptomycin phosphotransferase and was replaced with 
the 739 bp dhfr selection marker encoding for dihydrofolate reductase. The Tmpʳ marker was 
obtained from the plasmid pPLS076 by restriction digestion using PstI and KpnI (NEB England 
Biolabs Ltd., Pickering, ON, Canada) and was then polished using T4 DNA polymerase (NEB 
England Biolabs Ltd., Pickering, ON, Canada). The polished dhfr fragment was sub-cloned into 
a polished 5526 bp DNA fragment of pKNG101.  
v. Construction of the suicide vector pPLS109 
 
The suicide plasmid pKNG101 (Kaniga et al., 1991) was digested with the restriction 
enzymes SacI and NotI (NEB England Biolabs Ltd., Pickering, ON, Canada) to remove the 1460 
bp selection marker strAB encoding for streptomycin phosphotransferase and was replaced with 
the 1359 bp tet selection marker encoding tetracycline-resistance gene. The tetʳ marker was 
obtained from the plasmid pPLS077 by restriction digestion using PstI and KpnI (NEB England 
Biolabs Ltd., Pickering, ON, Canada) and was then polished using T4 DNA polymerase (NEB 
England Biolabs Ltd., Pickering, ON, Canada). The polished tet fragment was sub-cloned into a 




2.4 Preparation of E. coli chemically competent cells and transformation  
 
E. coli competent cells were prepared according to Inoue and colleagues (Inoue et al., 
1990). Briefly, E. coli were subcultured with a 1% v/v inoculum from an overnight culture and 
was grown to an absorbance (600nm) of 0.5. The culture was then chilled on ice for 15 minutes. 
Cells were harvested in a pre-chilled rotor at 5000 x g and resuspended in 0.4% of original 
volume of ice cold transformation buffer I (TFBI– 100 mM rubidium chloride (Fisher Scientific, 
Markham, ON, Canada), 50 mM manganese chloride (Bioshop Canada Inc., Burlington, ON., 
Canada), 30 mM potassium acetate (Bioshop Canada Inc., Burlington, ON., Canada), 10 mM 
calcium chloride (Bioshop Canada Inc., Burlington, ON, Canada), 15% w/v glycerol (Bioshop 
Canada Inc., Burlington, ON, Canada), pH 5.8). Cells were incubated on ice for exactly 5 
minutes, harvested as above and resuspended in 0.04% of original volume of ice cold 
transformation buffer II (TFBII– 10 mM 3-(N-morpholino) propanesulfonic acid, 10 mM 
rubidium chloride, 75 mM calcium chloride, 15% w/v glycerol, pH 6.5). Cells were incubated on 
ice for 60 minutes and 100 µl aliquots were made and immediately frozen on dry ice to be stored 
long term at -80°C. DNA Transformations were performed using the heat shock method 
(Sambrook and Russell, 2001). Briefly, 100-500 ng of DNA was added to 100 µl competent cells 
and incubated on ice for 10 minutes, then incubated at 42 °C for 45 seconds followed by 
incubation on ice for another 2 minutes. LB media (890 µL) was added to cells at room 
temperature and cells were recovered at 37 °C for 1 hour with shaking and plated on LB agar 





2.5 Preparation of A. baumannii electrocompetent cells and transformation by 
electroporation 
 
A. baumannii electrocompetent cells were prepared using the electroporation method 
previously described by Aranada et al., (2010). Briefly, A. baumannii were subcultured with a 
1% v/v inoculum from an overnight culture and grown to an absorbance600nm of 0.8. Cells were 
harvested in a pre-chilled rotor at 8000 x g by centrifugation and then washed 3 times with 10% 
(v/v) glycerol and finally resuspended in 500 μL of 10% (v/v) glycerol. An aliquot of 100 μL of 
the cell suspension was mixed with the 50-500 ng of DNA. The mixture was placed in a pre-
chilled sterile 2 mm electroporation cuvette (Thermo Fisher Scientific In, Mississauga, ON, 
Canada) and pulsed at 2.5 KV with default settings of 10 μF for 5 sec using Eppendorf 
electroporator Model 2510 (Eppendorf North America, Inc., Westbury, N.Y., USA). 
Immediately following the pulse, LB media (1 mL) was added to the cuvette at room temperature 
and cells were transferred to a microcentrifuge tube. Cells were recovered at 37 °C for 1 hour 
with shaking and plated on LB agar media containing the appropriate antibiotic for selection. 
2.6 Polymerase chain reaction (PCR)  
 
Extracted plasmids and genomic DNA were used as template for PCR amplification. 
PCR amplifications reactions were performed using variety of polymerases. Taq DNA 
polymerase (New England Biolabs, Pickering, ON, Canada) was used routinely for TA cloning 
and screening purposes, and Phusion HF (New England Biolabs, Pickering, ON, Canada) was 
used in the final step of Splicing by Overlap Extension (SOEing) reaction described below. All 
PCR polymerases and conditions were performed according to the manufacturer’s instructions. 
The annealing temperature (Ta) for each PCR primer was calculated based on the equation: 4 
(G+C) + 2(A +T) -5 (°C). 
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2.7 Splicing by overlap extension (SOEing) PCR 
 
The splicing Overlap Extension (SOEing) reaction was used to generate disrupted 
fragments for A1S_3229_30 with the purpose of creating gene knock-out using a previously 
described method (Choi and Schweizer, 2005) (Figure 2.1). This method consists of two steps of 
a PCR reaction. The first step involved amplifying the gentamycin resistant aacC1 and the 
flanking regions of the target gene/operon using Taq DNA polymerase (New England Biolabs, 
Pickering, ON, Canada). Gmʳ cassette was obtained by PCR amplification of aacC1 gene from 
50 ng of the plasmid pPS856 (Hoang et al., 1998). Flanking regions of the target gene/operon 
were amplified using the genomic DNA of A. baumannii ATCC17978 and adding engineered 
homologous regions to the aacC1 gene in each of the fragments. The sequences of the primers 
used in this work are described in Table 2.3. The resulting fragments Gmʳ (1,053 bp), the 5’- and 
3’-ends of the target gene/operon were purified from an agarose gel using the method described 
above and their concentrations determined spectrophotometrically (260nm) using the NanoDrop 
Lite Spectrophotometer (Thermo Fisher Scientific In, Mississauga, ON, Canada). Fifty 
nanograms of each of the three fragments was used as template for the second step of the PCR 
reaction. The reaction proceeded without any primers for 5 cycles (annealing temperature, 60˚C) 
after which the reaction was paused and the forward and reverse primers of 3’- and 5’-ends of 
the target gene were added and the reaction continued under the same conditions for 25 
additional cycles. Phusion HF and Taq DNA polymerase (New England Biolabs, Pickering, ON, 
Canada) were used for SOEing reactions following the manufacturer’s instructions. The resulting 
PCR product was gel purified and cloned into the pUC18 cloning vector, followed by sub-




Figure 2.1. Schematic illustration of mutant fragment generation by SOEing reaction for 
A1S_3229_30 operon. A PCR reaction was performed to amplify 276 bp of the 5’-end of the 
A1S_3229 gene, designed in the figure as A1S_3229’, and 220bp of the 3’-end of the A1S_3230 
gene, designed as A1S_3230’. These fragments were mixed with Gmʳ cassette (aacC1) to obtain 
the A1S_3229_30 deletion fragment. PCR products were visualized on a 0.8% agarose gel (A). 
These purified products which contained FRT overlapping sequences (blue boxes) were then 
assembled by SOEing reaction using PCR1 and PCR2 cycles. PCR1 reactions were prepared 
using equal amounts (50 ng) of each fragment in the absence of the primers, the run was paused 
after 5 cycles and primers were added to the reaction. Immediately after, PCR2 was run for 25 
cycles to allow the amplification of the SOEing product. The presence of 
ΔA1S_3229_30::GmFRT gene deletion fragment obtained from PCR2 was visualized on a 0.8% 










2.8 DNA sequencing and analysis  
 
Sanger DNA sequencing was performed at the Genome Quebec facility at McGill 
University, Montreal, QC. The sequence analysis was carried out using Basic Local Alignment 
Search Tool (BLAST) and Gene Construction Kit Software (Textco Biosoftware Inc, West 







2.9 Whole-genome sequencing for the clinical isolates A. baumannii AB030 and A. 
baumannii AB031 
 
i. Genomic DNA extractions  
 
Genomic DNA were extracted using the DNeasy Kit from Qiagen® (Qiagen, 
Mississauga, ON, Canada) as described above, and the MoBio® UltraClean® Microbial DNA 
Isolation Kit (MoBio Laboratories, Carlsbad, CA, US) following the detailed protocol provided 
by the manufacturer. The presence of DNA in each extraction was confirmed by agarose gel 
electrophoresis, and the final concentration and purity of DNA were determined using NanoDrop 
Lite Spectrophotometer (Thermo Fisher Scientific In, Mississauga, ON, Canada). 
ii. Sequencing and genome assembly 
 
The whole genome sequencing of A. baumannii AB030 and A. baumannii AB031 was 
carried out at the Genome Quebec facility at McGill University, Montreal, QC using the PacBio 
(Pacific Bioscience) sequencing platform using three SMRTcells. Assembly was carried out 
using the PacBio SMRT Analysis pipeline version 2.0.1, with 92X coverage for AB030 and 89X 
coverage for AB031 to give a single contiguous genome sequence for each strain.  
iii. Annotation and comparative genomics analysis 
 
Protein-coding genes were identified and annotated using RAST server (Aziz et al., 
2008), and National Center for Biotechnology Information (NCBI) Prokaryotic Genomes 
Annotation Pipeline. Multiple sequence alignments were performed with Basic Local Alignment 
Search Tool (BLAST), and ClustalW (Larkin et al., 2007). Putative promoter regions were 
analyzed using BPROM (Softberry Inc) (Solovyev and Salamov, 2011). The prediction of 
phosphorylation site was done using NetPhosBac 1.0 Server (Miller et al., 2009). Circular 
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alignment maps of AB030 and AB031 genomes obtained using the CGView (Stothard and 
Wishart, 2005) application. 
iv.  Nucleotide sequence accession numbers 
 
The genome sequences of AB030 and AB031 have been deposited in the NCBI/GenBank 
databases under the accession numbers CP009257 and CP009256, respectively. 
2.10 Quantitative-Reverse transcriptase polymerase chain reaction (qRT-PCR) 
 
i. RNA extraction 
 
Total RNA was extracted from cells using the RNeasy RNA isolation kit (Qiagen, 
Mississauga, ON, Canada). Briefly, cells were subcultured with a 1% v/v inoculum from an 
overnight culture and was grown to an absorbance (600nm) of 0.6. Cell pellets were frozen at -80 
°C for an overnight to facilitate cell lysis. Cells were then thawed at room temperature and 
resuspended in a containing 400 μg/mL lysozyme (Bioshop Canada Inc., Burlington, ON, 
Canada) and then transferred to a buffer containing guanidine-isothiocyanite, which inactivates 
RNases. Total RNA was precipitated with 95-100% ethanol and the solution was applied to an 
RNeasy silica membrane column. The membrane was washed with an ethanol containing wash 
buffer. RNA was eluted off of the column using RNase-free water. RNA concentrations were 
determined by the NanoDrop Lite Spectrophotometer (Thermo Fisher Scientific In, Mississauga, 
ON, Canada) RNA samples were stored at -80°C. 
ii. cDNA synthesis  
 
Contaminating genomic DNA was removed using the RNase-free DNase kit (Qiagen, 
Mississauga, ON, Canada) according to the manufacturer’s instructions. Briefly, 1 μg of total 
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RNA was incubated with 1.0 unit of DNase for 40 minutes at 37 °C, DNase was heat inactivated 
at 70 °C for 5 minutes and 800 ng of RNA was reverse transcribed with the iScript Reverse 
Transcriptase with random hexamer primers (BioRad Laboratories, Hercules, CA, USA) 
according to the manufacturer's instructions. No reverse transcriptase (NRT) controls were 
included with every cDNA preparation to rule out genomic DNA contamination. 
iii. Real-Time PCR  
 
Real-Time PCR was performed in the CFX-96 Thermal Cycler (BioRad Laboratories, 
Hercules, CA, USA) using Evagreen Sso-fast PCR supermix (BioRad Laboratories, Hercules, 
CA, USA). PCR conditions were as follows: 95 °C 3 minutes; (95 °C 10 seconds; 60 °C 30 
seconds) for 39 cycles. High-resolution melt conditions used were: 95 °C 10 seconds, 65 °C – 95 
°C in 0.5 °C increments, 5 seconds/ °C. The housekeeping gene 16S rRNA was used as a control. 
Reactions (15 μL) were set up using 300 nM primers and 5 μL of the cDNA template (diluted 
1:10). The efficiency of each primer set was determined by creating a standard curve using 10-
fold dilutions of pooled cDNA samples. Primer sets with efficiencies below 95% or above 105% 
were omitted. No Reverse Transcriptase (NRT) controls for the housekeeping genes were 
included to rule out contamination by genomic DNA. A No Template Control (NTC) for each 
gene was also included. Expression of target genes were normalized to the reference gene using 
the CFX Manager Software, Gene Expression Analysis tool (BioRad Laboratories, Hercules, 
CA, USA). The quality of the mRNA was assessed by ensuring the Ct-value remained constant 
for the housekeeping gene between runs. For gene expression analysis the ΔΔCt method was 
employed (Livak and Schmittgen, 2001). Data analysis was carried out using Bio-Rad CFX 




Table 2.1. List of strains used in the study 
Strains Relevant Characteristics Source 
E. coli 
DH5α F– Φ80lacZΔM15 Δ(lacZYA-argF) 
U169 recA1 endA1 hsdR17 (rK–, 
mK+) phoA supE44 λ– thi-1 gyrA96 relA1 
Laboratory 
collection 
MaH1 DH5α::mini-Tn7-pir-116 (Kvitko et al., 2012) 
SM10 thi-1 thr-1 leuB26 tonA21 lacY1 supE44 












ATCC17978 A. baumannii wild-type ATCC 
AB030 Clinical isolate (isolated from blood of a patient 
from Winnipeg, MB) 
(Fernando et al., 2013) 
AB031 Clinical isolate (isolated from blood of a patient 
from Toronto, ON) 






Table 2.2. List of plasmids used in the study 
Plasmids Relevant Characteristics Source 
pUC18 Apʳ, pUC18  Laboratory collection 
pGEMT-Easy Apʳ, TA PCR cloning vector Promega 
pKNG101 Strʳ, suicide vector contains the sacB gene that 
can be used as counter selectable marker. 
(Kaniga et al., 1991) 
pPLS076 Apʳ, Tmpʳ, pUC18-dhfr Laboratory collection 
pPLS077 Apʳ, Tetʳ, pUC18-tet Laboratory collection 
pPLS103 Tmpʳ, pKNG101-dhfr, Strʳ marker replaced with 
the dhfr gene. 
This Study 
pPLS104 Apʳ, pGEMT-Easy-A1S_2883_84 This study 
pPLS105 Apʳ, pGEMT-Easy-A1S_2006 This Study 
pPLS106 Apʳ, pGEMT-Easy-A1S_3375_76 This Study 
pPLS107 Apʳ, pGEMT-Easy-A1S_1232 This Study 
pPLS108 Apʳ, pGEMT-Easy-A1S_2906 This Study 
pPLS109 Tetʳ, pKNG101-tet, Strʳ marker replaced with 
the tet gene. 
This Study 
pPLS115 Apʳ, pGEMTEasy-A1S_1753_54 This Study 
pPLS116 Apʳ, pGEMTEasy-A1S_3229_30 This Study 
pPLS117 Apʳ, pGEMTEasy-A1S_0260_61 This Study 
pPLS125 Apʳ, Gmʳ, pUC18-3229::GmFRT This Study 
pPLS126 Tmpʳ, Gmʳ, pPLS103-Δ3229::GmFRT This Study 
pPLS143 Apʳ, pGEMTEasy-A1S_0478_79 This Study 
pPLS144 Apʳ, pGEMTEasy-A1S_2137_38 This Study 







Table 2.3. List of oligonucleotides used in the study 
 
Target Gene Oligonucleotide 
Name 
Sequence Reference 
A1S_2883_84 A1S_2883_2884_R CATTGTGGTTATCCACAGC Kumar Lab 
Database A1S_2883_2884_F GCTAGATCGGCTCATTACTA 
A1S_2750_51 A1S_2750_2751_R TTATGGACAGGCTGGGTCGT Kumar Lab 
Database A1S_2750_2751_F CTGGACATGTTGCACTCTTG 
A1S_2006 A1S_2006_R GCCGAGTTGCAATTGAGTC Kumar Lab 
Database A1S_2006_F CGCGTCGAATTGGCGCATTT 




A1S_1753_54 A1S_1753_1754_R ATGGCGAGAAGAGATTCGTAG Kumar Lab 
Database A1S_1753_1754_F GCGTATGATGAGTTGAAGCAC 
A1S_1393_94 A1S_1393_1394_R TAGCAGTGAGTCTGTATGCT Kumar Lab 
Database A1S_1393_1394_F GGATTGCTGGGTTTAATGCAGC 
A1S_0260_61 A1S_0260_0261_R TTGCAAGTAAAATCTCACAAGC Kumar Lab 
Database A1S_0260_0261_F CATACCTGAGGTTTGGTTTGG 
A1S_1232 A1S_1232_R  GACGCGCAAGGTTAGCAATTA Kumar Lab 
Database A1S_1232_F CATAGGAGATCGCTGGTCAC 




A1S_2906 A1S_2906_R GTTATAGCAGTTCAAGTAGTAG Kumar Lab 
Database A1S_2906_F AGCGGTTCCGACCAACAATG 
A1S_0748_49 A1S_0748_0749_R TGGAACCTGATGCAACTCAG Kumar Lab 
Database A1S_0748_0749_F GATACATGTAATGAGATTTATA
GG 
A1S_3229_30 A1S_3229_3230_F CCTAACCGATCCAATAATATATA Kumar Lab 
Database A1S_3229_3230_R GCGCTTTAAATGTTCAATTGCTC 
A1S_2137_38 A1S_2137_2138_R CTTTG AAACCCTTAGGGAG Kumar Lab 
Database A1S_2137_2138_F GCCATTAAAGCAATTGATGTAG 
A1S_0236 A1S_0236_RT_R AACGACGGGTTGTTTCTACG Kumar Lab 
Database A1S_0236_RT_F TATCGTTCGCCAACAACATC 
A1S_3375 A1S_3375_RT_R TGCAAGCAGACGGTATTCTG Kumar Lab 
Database A1S_3375_RT_F CAATTGATGCCAATGGTTTG 
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A1S_2883 A1S_2883_RT_F GATGTTGCCGACCGAGTTAT Kumar Lab 
Database A1S_2883_RT_R TCCACTCATGACGGTTACCA 
A1S_2751 A1S_2751_RT_R ATACGGGCAAGCAACTCATC Kumar Lab 
Database A1S_2751_RT_F TTACAAAACCGTGTCGATGG 
A1S_3229 A1S_3229_RT_F CTCGTGAGGGTCAAATCGTT Kumar Lab 
Database A1S_3229_RT_R TGTCGCGTGTTAAAGGTTCA 
A1S_0261 A1S_0261_RT_F CCAGCTAACACAAGCACAGC Kumar Lab 
Database A1S_0261_RT_R CCAGCTAACACAAGCACAGC 
A1S_2137 A1S_2137_RT_R GTGCTTCTTGCTGGATTGGT Kumar Lab 
Database A1S_2137_RT_F TGCTTTGCTAGATGCTGGTG 
A1S_2006 A1S_2006_RT_F GTTGAAAAGGCCAAAGTGCT Kumar Lab 
Database A1S_2006_RT_R GTGCCATTTCTCCAATCGTT 
A1S_1394 A1S_1394_RT_R TTCACTGTCCGTGGACTCAG Kumar Lab 
Database A1S_1394_RT_F AAATATTGCCCGCAGTTGAC 
bfmR bfm_RT_R CATGAGATACCGCCCTCATT Kumar Lab 
Database bfm_RT_F TCCTATTGAGGGAAGCGATG 
16S 16S_F_RT GGAGAAAGCAGGGGATCTTC (Fernando et 
al., 2013) 16S_R_RT ATCCTCTCAGACCCGCTACA 
GmFRT GmFRT-UP CGAATTAGCTTCAAAAGCGCTCT
GA 







































3.1 Cloning of two component systems operons of Acinetobacter baumannii 
 
i. Amplification and cloning of two component systems operons. 
 
The PCR amplifications of A1S_1232, A1S_2006, A1S_2906, A1S_3375_76, 
A1S_0260_61, A1S_2750_51, A1S_1753_54, A1S_2883_84, A1S_0748_49, 1977_78, 
A1S_3229_30, A1S_2137_38, and A1S_1394_95 have been standardized using the A. baumannii 
ATCC17978 genomic DNA as template, as seen in Figure 3.1.A. The PCR product of each TCSs 
operon was purified and then cloned into pGEMT-Easy vector. Successful clones were 





Figure 3.1. Amplification and cloning of TCSs operons of A. baumannii. A) The TCSs 
operon was amplified using genomic DNA of A. baumannii as a template using PCR. Lane 1 was 
the 10kb DNA marker; 2. A1S_1232; 3. A1S_2006; 4. A1S_2906; 5. A1S_3375_76; 6. 
A1S_0260_61; 7. A1S_2750_51; 8. A1S_1753_54; 9. A1S_2883_84; 10. A1S_0748_49; 11. 
A1S_3229_30; 12. A1S_1977_78; 13. A1S_2137_38; 14. A1S_1394_95; 15. 10kb DNA marker. 
B) The TCSs operons were cloned into pGEMT-Easy vector, and clones were confirmed using 
restriction digestion. The size of the fragments expected are 3kb represents the size of the vector. 
Lane 1 was the 10kb DNA marker; 2. pPLS107; 3. pPLS105; 4. pPLS108; 5. pPLS106; 6. 









3.2 Creation of genetic tools for Acinetobacter baumannii 
 
i. Construction of the suicide plasmid pPLS103 to create gene knockouts in A. 
baumannii. 
 
The trimethoprim-resistant suicide plasmid pPLS103 was constructed with the purpose of 
creating mark-less gene knockouts in MDR A. baumannii. The resulting plasmid was named 
pPLS103, and its identity was confirmed by restriction digestion, as seen in Figure 3.2.A.The 
sizes of the fragments are as expected: 3097 bp, 1570 bp, and 1565 bp (Figure 3.2). 
ii. Construction of the suicide plasmid pPLS109 to create gene knockouts in A. 
baumannii. 
 
The tetracycline-resistant suicide plasmid pPLS109 was constructed with the purpose of 
creating mark-less gene knockouts in intrinsically streptomycin resistant A. baumannii. The 
resulting plasmid was named pPLS103, and its identity was confirmed by restriction digestion, 




Figure 3.2. Construction of the suicide vector pPLS103. The suicide vector pKNG101 (6986 
bp) contains the pir minus origin of replication of R6K (oriR6K), multiple cloning sites (MCS), 
the strAB genes encoding for streptomycin phosphotransferase, origin of transfer (oriT), and 
sacB encodes of levansucrase as a positive selection marker for the excision of the plasmid. The 
trimethoprim-resistant suicide vector was named pPLS103, and restriction digestion was 
performed to confirm the plasmid identity. Lane 1, 10 kb DNA marker. Lane 2, pKNG101 
digested with EcoRI, and the expected fragments sizes are 3097 bp, 2319 bp, and 1570. Lane 3, 










Figure 3.3. Construction of the suicide vector pPLS109. The suicide vector pKNG101 (6986 
bp) contains the pir minus origin of replication of R6K (oriR6K), multiple cloning sites (MCS), 
the strAB genes encoding for streptomycin phosphotransferase, origin of transfer (oriT), and 
sacB encodes of levansucrase as a positive selection marker for the excision of the plasmid. The 
tetracycline-resistant suicide vector was named pPLS109, and restriction digestion was 
performed to confirm the plasmid identity. Lane 1, 10 kb marker. Lane 2, pKNG101 digested 
with EcoRI, and the expected fragments sizes are 3097 bp, 2319 bp, and 1570. Lane 3, pPLS109 








3.3 Expression of two component systems in clinical isolates of Acinetobacter baumannii  
 
i. Comparative quantitative real-time (qRT-PCR) analysis of mRNA expression of twelve 
TCSs. 
 
Analysis of the expression of TCSs was carried out on two blood isolates A. baumannii 
AB030 and A. baumannii AB031, which display very different antibiotic sensitivity profiles 
(Fernando et al., 2013). Comparison of global regulatory mechanisms that control multidrug 
resistance between these two strains can be an effective way to understand the mechanisms of 
multidrug resistance in A. baumannii. Since TCSs are known to play a role in regulating 
multidrug resistance and virulence in various pathogens, characterization of genes that encode 
TCSs in AB030 and AB031 is the first logical step in deciphering these mechanisms. 
 Ten putative response regulators genes were selected for this analysis based on the fact 
that these are conserved among the all A. baumannii sequenced strains (Adams et al., 2008). 
These ten putative and characterized response regulators are A1S_0236, A1S_2006, A1S_1978, 
A1S_3375, A1S_1753, A1S_1394, A1S_2137, A1S_2751, A1S_3229, and bfmR. 
 Differential expressions were observed in the well characterized TCSs (bfmR and adeR) 
between A. baumannii AB030 and A. baumannii AB031 compared to the control strain A. 
baumannii ATCC17978. bfmR showed 70-fold overexpression in A. baumannii AB030 and 5-
fold overexpression in A. baumannii AB031. On the other hand, A1S_0236, A1S_3375, 
A1S_2751, and A1S_1394 were all expressed in A. baumannii AB030 and A. baumannii AB031 




Figure 3.4. Expression of ten putative response regulators genes in A. baumannii clinical 
isolates. Expression of A1S_0236, A1S_2006, A1S_1978, A1S_3375, A1S_1753, A1S_1394, 
A1S_2137, A1S_2751, A1S_3229, and bfmR was measured using qRT-PCR in A. baumannii 
AB030 and A. baumannii AB031. Differential expression of the six response regulators genes 
A1S_1753, A1S_1978, A1S_2006, A1S_2137, A1S_3229, and bfmR in A. baumannii AB030 and 
A. baumannii AB031 compared to the control strain A. baumannii ATCC17978. 16S rRNA was 
used as the housekeeping gene, and A. baumannii ATCC17978 was used as the control strain. 
Each reaction contained the no-template and no-RT controls. Asterisk indicates differences in 
expression relative to parent strain ATCC17978, P<0.05. Data shown is representative of at least 

























ii. Differential expression of six different response regulators genes 
 
Six response regulators were differentially expressed between A. baumannii AB030 and 
A. baumannii AB031 compared to the control strain A. baumannii ATCC17978. These genes are 
A1S_1753, A1S_1978, A1S_2006, A1S_2137, A1S_3229, and bfmR. (Figure 3.4) 
These results taken together, demonstrate an ideal start to identify suitable candidates to 

















3.4 Whole-genome sequencing of Acinetobacter baumannii AB030 and AB031. 
 
i. Whole-genome sequencing of A. baumannii AB030 and A. baumannii AB031 
 
Genomes of AB030 and A. baumannii AB031 was sequenced using Pacific bioscience 
(PacBio) sequencing platform, assembled, and annotated for this analysis. The genome size of 
AB030 was 4,335,793 bp with a G+C content of 39% and the number of ORFs was 4132 (Figure 
3.5). 
Interestingly, the AB031 genome appears to be relatively small in comparison to AB030, 
and the genome size of AB031 was 3,803,317 bp with a G+C content of 38% and the number the 
number of ORFs was 3456 (Figure 3.6). 
Circular alignment maps of AB030 and AB031 was obtained from using the CGView 
(Stothard and Wishart, 2005) application, a comparative genomics tool was used to visualize the 
sequence feature information. For each of these maps a BLAST comparison was done using 
AB030 and AB031 against each other; the clinical isolate AB307-0294 (GenBank accession no. 
CP001172), which was shown as the closest neighbor to both AB030 and AB031, and 
ATCC17978 (GenBank accession no. CP000521). The gaps in the BLAST comparison results 
indicate the unique regions in the AB030 and AB031 genomes. For the BLAST results rings, the 
overlapping hits appear as darker regions. The innermost two rings show GC content and GC 




Figure 3.5. Circular representation of genome of A. baumannii AB030. Circles display (from 
outside in order of) (i) open reading frames (>100 codons) in the clockwise and 
counterclockwise direction respectively; (ii) comparison with three selected genomes by BLAST 










Figure 3.6. Circular representation of genome of A. baumannii AB031. Circles display (from 
outside in order of) (i) open reading frames (>100 codons) in the clockwise and 
counterclockwise direction respectively; (ii) comparison with three selected genomes by BLAST 












ii. Identification and comparison of TCSs in A. baumannii AB030 and A. baumannii 
AB031 genomes 
 
The first Sensor kinase (SK) and response regulator (RR) genes in A. baumannii were 
identified in the two strains ATCC17978 and AB0057 (Adams et al., 2008). A total of nineteen 
SK genes and seventeen RR genes were identified in the genome of the wild-type strain 
ATCC17978. Like in other bacterial species SKs and RRs were encoded by clusters of adjacent 
genes, sixteen putative clusters of complete TCSs genes were identified in ATCC17978. For the 
remaining SK or RR genes, their partner genes could not be predicted from genetic organization 
and, therefore, they were considered as orphan SKs or RRs. Five of the fifteen TCSs genes 
clusters were well characterized in ATCC17978: BfmRS, AdeRS, BaeSR, PmrAB, and GacSA.  
BLAST search against the sequenced genome of AB030 identified seventeen SK genes 
and sixteen RR genes, and a total of 15 TCSs genes clusters were common between AB030 and 
AB031 and ATCC17978. In AB031, two additional TCSs gene clusters were identified, these 
two TCSs cluster were only common between AB031 and AB0057. Results are listed in Table 
3.1.  
The TCSs cluster A1S_2937_38 was absent in AB030 and also missing in AB031. In 
AB031, two more TCSs gene clusters were identified that are homologous to AB57_2542_43 
and AB57_2550_51, found only in the clinical isolate AB0057 (GenBank accession no. 
CP001182) (Table. 3.2). 
Taken together, comparative genome analysis of the TCSs among these strains provides 




Table 3.1. Summary of the absence and presence of putative two component systems genes 
in the genomes of A. baumannii AB030 and A. baumannii AB031. Closest orthologs are 










response regulator (PilR) IX87_15710 IX88_03400 
      sensor histidine kinase (PilS) IX87_15730 IX88_03405 
A1S_0236 GacA (Cerqueira et a., 2013) sirA sirA 
A1S_0260 
A1S_0261 
sensor histidine kinase (AlgZ) IX87_15850 IX88_03525 
response regulator (AlgR) IX87_15855 IX88_03530 
A1S_2938 
A1S_2937 
sensor kinase (CusS) - - 
response regulator (CusR) - - 
A1S_0574 sensor histidine kinase (BarA) IX87_17370 IX88_05080 
A1S_0748 
A1S_0749 
BfmS (Tomaras et al., 2008) IX87_18030  IX88_05725 
BfmR (Tomaras et al., 2008) IX87_18025 IX88_05720 
A1S_1393 
A1S_1394 
sensor histidine kinase IX87_03280 IX88_08935 
response regulator  IX87_03275 IX88_08940 
A1S_1753 
A1S_1754 
AdeR (Marchand et al., 2004) IX87_20165 IX88_10940 
AdeS (Marchand et al., 2004) IX87_20170 -* 
A1S_1977 
A1S_1978 
sensor histidine kinase (GlnL) IX87_21680 IX88_12105 
response regulator (GlnG) glnG glnG 
A1S_2006 response regulator (NasT) -* IX88_12260 
A1S_2137 
A1S_2138 
response regulator (KdpE) IX87_06675 IX88_13225 





Sensor kinase IX87_13525 IX88_01290 
response regulator IX87_13540 IX88_01300 
A1S_3375 
A1S_3376 
response regulator (PhoB) IX87_13940 IX88_01695 
sensor histidine kinase (PhoR) IX87_13945 IX88_01700 
A1S_2287 
A1S_2288 
sensor histidine kinase (QseC) IX87_07540 IX88_14435 
response regulator IX87_07545 IX88_14440 
A1S_2750 
A1S_2751 
PmrA (Arroyo et al., 2011) IX87_10330 IX88_16920 
PmrB (Arroyo et al., 2011) IX87_10335 IX88_16925 
A1S_2811 sensor histidine kinase IX87_10935 IX88_17240 
A1S_2814 
A1S_2815 
sensor histidine kinase IX87_10950 IX88_17255 
response regulator (Pil)G IX87_10955 IX88_17260 
A1S_2883 
A1S_2884 
BaeS (Lin et al., 2013) IX87_11300 IX88_17590 
BaeR ((Lin et al., 2013) IX87_11305 IX88_17595 
A1S_2906 sensor histidine kinase IX87_11440 IX88_17710 
A1S_3229 
A1S_3230 
response regulator (OmpR) IX87_13010 IX88_00910 








Table 3.2. The presence of putative two component systems genes in the genomes of A. 
baumannii AB031. Closest orthologs are indicated in parenthesis. References are provided for 
gene products characterized in A. baumannii. 
A. baumannii 
AB0057 






sensor kinase - IX88_13575 
response regulator  - IX88_13580 
AB57_2550 
AB57_2551 
heavy metal sensor kinase - IX88_13615 
























iii. Identification and analysis of disruption of A1S_2006 in AB030. 
 
Analysis of TCSs in the whole genome of A. baumannii AB030 demonstrated that 
A1S_2006, an orphan response regulator, was disrupted with 3902 bp DNA insertion in length to 
generate A1S_2006 mutant strain, as shown in Figure 3.7. Blast search of this additional 3902 bp 
showed similarities (80%-90%) to insertion elements known among A. baumannii such as 
ISAba1element, blaOXA-23 gene, transposon Tn2006, and transposon Tn2008. 
iv. Identification and analysis of disrupted A1S_1754 (adeS) in AB031 
 
A1S_1754 encodes for the sensor kinase of AdeRS system in A. baumannii. Analysis of 
TCSs in the whole genome of A. baumannii AB031 obtained an 1189 bp additional DNA 
insertion in the gene A1S_1754 (adeS), as shown in Figure 3.8. BLAST search of this additional 
1189 bp additional DNA insertion showed 100% identity to the ISAba1 insertion element in A. 
baumannii resulted in a disruption in adeS. 
v. Analysis of the A1S_1753 (adeR) promoter region from A. baumannii AB031. 
 
The promoter regions of five TCSs operons (A1S_2006, A1S_1753_54, A1S_1977_77, 
3229_30, and 2137_38) from AB030 and AB031 were analyzed with the purpose of establishing 
possible differences between strains expressing and those not expressing the TCSs gene. Only 
A1S_1753_54 (adeRS) promoter showed one nucleotide difference in A. baumannii AB031 
which showed no expression of the A1S_1753_54. The alignment of the A1S_1753_54 promoter 




Figure 3.7. Schematic representation of the genetic organization on A1S_2006 based on 
RAST server annotation. A) A. baumannii AB030 chromosome with the 3902 bp additional 
DNA insertion. B) A. baumannii ATCC17978 chromosome encoding for A1S_2006 with 
























Figure 3.8. Schematic representation of the genetic organization on A1S_1753 based on 
RAST server annotation. A) A. baumannii AB031 chromosome with the 1189 bp additional 
DNA insertion. B) A. baumannii ATCC17978 chromosome encoding for A1S_1753 with 
































Figure 3.9. Sequence alignment of A1S_1753_54 (adeRS) promoter region from AB030, 
AB031, and ATCC17978. Strains AB030 and ATCC17978 express A1S_1753, and their 
sequences showed the presence of a Thymine (T) nucleotide in -10 motif, the nucleotide in this 
position is showed bold and underlined. AB031 showed expression of A1 gene presented a 
Guanidine (G) in this position instead. The -35 and -10 motifs of promoters are indicated in 
























3.5 Attempts to create gene-knock out of A1S_3229_30 in Acinetobacter baumannii 
 
i. A1S_3229 expression and sequence analysis 
 
qRT-PCR analysis of A1S_3229 demonstrated an approximately 2-fold change of 
expression between A. baumannii AB030 and A. baumannii AB031 compared to the control 
strain A. baumannii ATCC17978 (Figure 3.4). In addition, A1S_3229_30 operon shows 73% 
identity to the AmgRS system of Pseudomonas aeruginosa (Figure 3.5), making it a good 
candidate for this study. 
ii. Generation of A1S_3229_30 deletion fragment 
 
A gene-knock out fragment for A1S_3229_30 operon was created using the technique 
described by Choi and Schweizer (2005) Annealing of the three fragments 3’ and 5’ ends from 
A1S_3229_30 operon and aacC1 gene is described in Fig 3.6.A allow the generation of the gene 
deletion fragment for A1S_3229_30 operon, ΔA1S_3229_30::GmFRT, as seen in Fig. 3.6.C. The 
pUC18 plasmid was digested with SmaI, and ligated with ΔA1S_3229_30::GmFRT, to obtain the 




Figure 3.10. A1S_3229_30 sequence analysis. Alignment of amino acids sequences showing 
similarities of A1S_3229_30 to AmgRS and A1S_3229_30 shows 73% identity to the AmgRS 
system in P. aeruginosa PAO1. The amino acids underlined indicate the predicted 
phosphorylation site of A1S_3229_30 sensor kinase. The prediction of phosphorylation site was 


















AB030           MDRLLQRELFSLIVLDFMLPVEDGLSICRRLRQSNIDTPIIMLTARGSDSDRIAGLEAGA 60 
AB031           MDRLLQRELFSLIVLDFMLPVEDGLSICRRLRQSNIDTPIIMLTARGSDSDRIAGLEAGA 60 
ATCC17978       MDRLLQRELFSLIVLDFMLPVEDGLSICRRLRQSNIDTPIIMLTARGSDSDRIAGLEAGA 60 
PAO1            MDRLLSRELFQLVVLDLMLPGEDGLTACRRLREQNNQVPIIMLTAKGDEGSRIQGLELGA 60 
                *****.****.*:***:*** ****: *****:.* :.*******:*.:..** *** ** 
 
AB030           DDYLPKPFNPNELLARIRAVLRRQVREVPGAPSQQVEVVSFGPWSLDLSTRTLTREGQIV 120 
AB031           DDYLPKPFNPNELLARIRAVLRRQVREVPGAPSQQVEVVSFGPWSLDLSTRTLTREGQIV 120 
ATCC17978       DDYLPKPFNPNELLARIRAVLRRQVREVPGAPSQQVEVVSFGPWSLDLSTRTLTREGQIV 120 
PAO1            DDYLAKPFNPRELLARIKAVLRRQAPLVPGAPAGADEVVTFGDYQLFLATRELKKGDEVH 120 
                ****.*****.******:******.  *****:   ***:** :.* *:** *.: .::  
 
AB030           TLTTGEFAVLKALVQHPREPLTRDKLMNLARGREWGAMERSIDVQVSRLRRLIEDNPARA 180 
AB031           TLTTGEFAVLKALVQHPREPLTRDKLMNLARGREWGAMERSIDVQVSRLRRLIEDNPARA 180 
ATCC17978       TLTTGEFAVLKALVQHPREPLTRDKLMNLARGREWGAMERSIDVQVSRLRRLIEDNPARA 180 
PAO1            MLTTGEFAVLKALVQHAREPLTRDKLMNLARGREWDALERSIDVQISRLRRLIEPDPSKP 180 
                 ***************.******************.*:*******:******** :*::. 
 
AB030           RYIQTVWGVGYVFVPDGAEMRTTILVLLVVLFSLFMSLWFFWRTLYLPEIQQHARYLAVE 240 
AB031           RYIQTVWGVGYVFVPDGAEMRTTILVLLVVLFSLFMSLWFFWRTLYLPEIQQHARYLAVE 240 
ATCC17978       RYIQTVWGVGYVFVPDGAEMRTTILVLLVVLFSLFMSLWFFWRTLYLPEIQQHARYLAVE 240 
PAO1            RYIQTVWGVGYVFVPDGNARKAMKTPLWFPQSFFARTLWLVLIVVLFSKALTLVYLLMNE 240 
                *****************   ::    * .    :  :**:.  .: :.:    .  *  * 
 
AB030           LELVNNPN-------IRIFHRDSEVDVDTWLRNRVGIEYVTNPKEYPSVRDKIIAEFFTN 293 
AB031           LELVNNPN-------IRIFHRDSEVDVDTWLRNRVGIEYVTNPKEYPSVRDKIIAEFFTN 293 
ATCC17978       LELVNNPN-------IRIFHRDSEVDVDTWLRNRVGIEYVTNPKEYPSVRDKIIAEFFTN 293 
PAO1            DVIVDRQYSHGAALTIRAFWAADE-ESRAAIAKASGLRWVPSSADQPGEQHWPYTEIFQR 299 
                  :*:.         ** *   .* :  : : :  *:.:*... : *. :.   :*:* . 
 
AB030           QVEQKLANEIGAKDVTVYFQFKPSPRIWIQTPEMHGNWVREPLKTYANYSPELL--VGWV 351 
AB031           QVEQKLANEIGAKDVTVYFQFKPSPRIWIQTPEMHGNWVREPLKTYANYSPELL--VGWV 351 
ATCC17978       QVEQKLANEIGAKDVTVYFQFKPSPRIWIQTPEMHGNWVREPLKTYANYSPELL--VGWV 351 
PAO1            QMQMELG-----PDTETRLRIHQPSQLWVRAPSLGEGWLAVPLYPHPLRGQRIWSVLGWF 354 
                *:: :*.      *. . :::: ..::*:::*.:  .*:  ** .:.  . .:   :**. 
 
AB030           VGVPLVSAIIILILVRQMNRPLRRLQNAANEYSKSGTAPYLDTNHGPLEIRQVNQAFNRM 411 
AB031           VGVPLVSAIIILILVRQMNRPLRRLQNAANEYSKSGTAPYLDTNHGPLEIRQVNQAFNRM 411 
ATCC17978       VGVPLVSAIIILILVRQMNRPLRRLQNAANEYSKSGTAPYLDTNHGPLEIRQVNQAFNRM 411 
PAO1            LGIGLLSTAAAWIFVRQLSQPLKRLVVAARQFGQGRSVRLPLGPETPSEMAEVYRAFNQM 414 
                :*: *:*:    *:***:.:**:**  **.::.:. :.      . * *: :* :***:* 
 
AB030           VYTLEQTERERRIMLAGISHDLRTPLTRIRLTAEMLP--DEFLREGLVYDVDDMDAILNQ 469 
AB031           VYTLEQTERERRIMLAGISHDLRTPLTRIRLTAEMLP--DEFLREGLVYDVDDMDAILNQ 469 
ATCC17978       VYTLEQTERERRIMLAGISHDLRTPLTRIRLTAEMLP--DEFLREGLVYDVDDMDAILNQ 469 
PAO1            AEDIEQGGRERELMLAGVSHDLRTPLTRLRLSLELLPESEREMVEDMIRDIEDMDAILDQ 474 
                .  :**  ***.:****:**********:**: *:**  :. : *.:: *::******:* 
 
AB030           FISYMRDGSDEELKDTNINILLQELVVQFKP--LDIRFNMQDVPIIPARSLSLKRLIANL 527 
AB031           FISYMRDGSDEELKDTNINILLQELVVQFKP--LDIRFNMQDVPIIPARSLSLKRLIANL 527 
ATCC17978       FISYMRDGSDEELKDTNINILLQELVVQFKP--LDIRFNMQDVPIIPARSLSLKRLIANL 527 
PAO1            FLAFIRDGRDEPVEEGDLTDLVREVVAPFNQTREQVRMALQPVPAMPLRRVSMKRLLGNL 534 
                *::::*** ** ::: ::. *::*:*. *:    ::*: :* ** :* * :*:***:.** 
 
AB030           INNAKRYGAEPIELSAKVENE----HILITVADHGEGIPEDQIEELMQPFVRGNSARTIQ 583 
AB031           INNAKRYGAEPIELSAKVENE----HILITVADHGEGIPEDQIEELMQPFVRGNSARTIQ 583 
ATCC17978       INNAKRYGAEPIELSAKVENE----HILITVADHGEGIPEDQIEELMQPFVRGNSARTIQ 583 
PAO1            IDNALNHGGGSVEVASYVAGESAAPYVVLSVLDRGQGIDPAEVDSIFNPFIRGDKARGGK 594 




AB030           GSGLGLAIVKRIVDIHQGEIQIHNREQGGLEVIISLPIPKPAPEENTTHNPLEKIKQTLS 643 
AB031           GSGLGLAIVKRIVDIHQGEIQIHNREQGGLEVIISLPIPKPAPEENTTHNPLEKIKQTLS 643 
ATCC17978       GSGLGLAIVKRIVDIHQGEIQIHNREQGGLEVIISLPIPKPAPEENTTHNPLEKIKQTLS 643 
PAO1            GTGLGLAIVKRIAAQHGGSVELRNRDGGGLEARVCLPLGLLLPRGAA------------- 641 
                *:**********.  * *.::::**: ****. :.**:    *.  :              
 
AB030           ERF 646 
AB031           ERF 646 
ATCC17978       ERF 646 
PAO1            --- 
Figure ii.1 
(-) Gaps/insertions 
(*) Identical residue  
(:) Strongly similar residue (scoring >0.5 in the Gonnet PAM matrix) 




Figure 3.11. Schematic illustration A1S_3229_30 knock out fragment generation by overlap 
extension PCR. During the first round PCR (PCR1), a 276 bp fragment from the 5' end and 220 
bp fragment from the 3' ends of A1S_2339_30 were annealed together with aacC1 using the 
splicing overlap extension reaction as described in Figure 3.6.A and B. The 1511 bp assembled 
fragment was then amplified using full length primers A1S_3229_30_F and A1S_3229_30_R. 
The A1S_3229_30 operon deletion fragment obtained from the SOEing PCR reaction shown in 
Fig. 3.6.C was ligated into pUC18 plasmid digested with SmaI restriction enzyme. 
ΔA1S_3229_30::GmFRT operon deletion fragment obtained from pPLS125 was ligated into 
pPLS103 plasmid digested with SmaI restriction enzyme. Verification of the plasmid 
composition was done by restriction digestion using EcoRI resulting in 3097 bp, 2280 bp, 1565 
bp, and 575 bp sizes as seen in Fig. 3.6.E.  E) Lane 1, pPLS103 digested with EcoRI, and 
expected sizes are 3097 bp, 1570 bp, and 1565 bp. Lane 2, pPLS126 digested with EcoRI, and 
expected sizes are 3097 bp, 2280 bp, 1565 bp, and 575 bp. Lane 3, 10 kb DNA marker, Lane 4, 
pPLS103 digested with KpnI, and expected sizes are 2001 bp, and 4231. Lane 2, pPLS126 











iii. Construction of pPLS126 the suicide plasmid containing ΔA1S_3229_30::GmFRT 
 
The suicide plasmid pPLS103 was digested with SmaI, and the ΔA1S_3229_30::GmFRT 
deletion fragment was obtained from pPLS125 digested by KpnI and SphI and ligated to 
ΔA1S_3229_30::GmFRT, to obtain the pPLS126 plasmid and transformed into MaH1 competent 
cells. To confirm the identity of the construct screening was performed by restriction enzymes 
using EcoRI in a single digestion and the product of this digestion was a 3097 bp, 2280 bp, 1565 
bp, and 575 bp. Another single digestion was performed by KpnI, and the product of this 































4.1 Expression of two component systems in clinical isolates of Acinetobacter baumannii 
AB030 and AB031. 
 
It has been reported in different pathogens that a variety of two component systems 
regulate complex antibiotic resistance and virulence processes (Gooderham and Hancock, 2009; 
Merighi et al., 2006; Stephenson and Hoch, 2002). Therefore, identification and development of 
new inhibitors of TCSs as potential targets, especially considering the fact they are not present in 
mammalian cells, provide new potentially therapeutic options for the treatment of drug-resistant 
bacterial infections. A few studies have characterized TCSs and their role in MDR A. baumannii 
(Tomaras et al., 2008; Marchand et al., 2004; Lin et al., 2013; Cerqueira et al., 2013; Arroyo et 
al., 2011); however, a number of putative two component systems encoded in the genome of A. 
baumannii that await detailed characterization. It is likely that some of these uncharacterized 
systems have global regulatory mechanisms that regulate antibiotic resistance and virulence 
processes in MDR A. baumannii. For this purpose, this research analyzed the expression of TCSs 
response regulators (characterized as well as yet uncharacterized) in two clinical isolates from 
Canadian hospitals, which display very different antibiotic susceptibility profiles (Fernando et 
al., 2013). The analysis observed differential expressions of six TCSs response regulators in both 
clinical isolates AB030 and AB031, these genes are bfmR (A1S_0748_49), adeRS (A1S_1753), 
A1S_1978, A1S_2137, A1S_2006, and A1S_3229. bfmR has been shown to play a role in A. 
baumannii virulence (Tomaras et al., 2008), and adeRS was reported to play a major role in 
antibiotic resistance (Marchand et al., 2004), suggesting the involvement of TCSs in the 
pathogenicity and antibiotic resistance of A. baumannii. By analyzing the expression of as yet 
uncharacterized TCSs in two blood isolates AB030 and AB031, we aim to identify and 
characterize novel TCSs that act as global regulators of antibiotic resistance and virulence in the 
MDR A. baumannii. 
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The ability of A. baumannii to generate biofilms represents an important virulence factor 
as it contributes to the pathogen’s ability to survive in the host and the environment, and develop 
resistance to antibiotics (Roca et al., 2012). Biofilm formation is controlled by BfmRS in A. 
baumannii ATCC19606. It has been reported that inactivation of the TCSs BfmRS abolishes the 
biofilm formation (Tomaras et al., 2008). Interestingly, bfmR showed a higher expression in the 
clinical isolate AB030 than in AB031; however, preliminary virulence phenotypic analysis of 
AB030 and AB031 revealed that AB031 forms more biofilm than AB030 (Kumar, unpublished). 
In addition, genomic analysis showed that BfmRS was highly conserved among ATCC17978, 
AB030 and AB031 genomes as seen in Appendix 1. Therefore, our data suggest that other 
factors are involved in the formation of biofilm and regulation of other virulence factors. 
The expression of AdeABC efflux pump is tightly regulated by the two component 
systems AdeRS in A. baumannii. The adeRS (A1S_1753_54) operon is located upstream of 
adeABC operon and is transcribed divergently. The efflux pump AdeABC is responsible for 
resistance to aminoglycosides, tetracycline, erythromycin, chloramphenicol, trimethoprim, and 
fluoroquinolones. Disruption of adeR and adeS genes by insertional mutagenesis resulted in 
increased susceptibility of the mutant strains of A. baumannii to aminoglycosides and other 
substrates of the pump (Marchand et al., 2004), indicating that the AdeRS system is a positive 
regulator of the AdeABC pump.  
Differences in the expression of the pump AdeABC were reported in both clinical 
isolates AB030 and AB031, and it was found that the expression level of AdeABC was about 4-
fold higher in AB030 than in AB031 (Fernando et al., 2013). Overexpression of the response 
regulator adeR was observed in AB030, suggesting that overexpression of AdeRS system results 
in overexpression of AdeABC efflux pump which may at least partly explain the MDR 
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phenotype in AB030. In addition to the overexpression of the AdeRS system, mutations in adeS 
or adeR also contribute to AdeABC overexpression (Marchand et al., 2004). We found novel 
mutations in adeR gene that encodes for AdeR (response regulator) in AB030 as seen in 
Appendix 2, and it is possible that these novel mutations played a role in the observed 
overexpression of adeR (A1S_1753) in AB030 but still; however, further analysis of these point 
mutations is required in order to validate any of these explanations. 
On the other hand, adeR expression was not observed in AB031 and it likely to be reason 
for the lower expression of AdeABC efflux pump in comparison to AB030. However, the 
expression of AdeABC in AB031 is still higher than that in ATCC17978 suggesting that the 
regulation of adeABC operon expression is complicated, and not merely dependent on the 
AdeRS system. The analysis of the predicted sigma70 promoter region of adeR (A1S_1753) in 
AB031 showed a GT substitution in the predicted -10 motif (Figure 3.9), this could affect the 
binding of the DNA-dependent RNA-polymerase to DNA modulating the gene transcription of 
adeR (A1S_1753). In addition, analysis of adeRS (A1S_1753_54) sequence in AB031 showed 
1189 bp additional DNA insertion in the gene A1S_1754 (adeS) as seen in Figure 3.8, and it is 
likely that this additional DNA insertion could result in a truncated, putatively non-functional, 
adeS sensor kinase. Further studies are necessary to determine the role of AdeRS system in the 
regulation of the AdeABC efflux pump in AB031, and possibly characterize regulator(s) that 
play a role in regulation of AdeABC efflux pump other than AdeRS system. 
In addition to the AdeRS system, overexpression of the orphan TCSs response regulator 
A1S_2006 was observed in AB030. However, the whole-genome sequencing analysis in of TCSs 
in AB030 revealed the presence of 3902 bp DNA insertion in length to generate A1S_2006 
mutant strain, as seen in Figure 3.7. It is evident that this insertion renders A1S_2006 non-
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functional. Interestingly, we still observed an overexpression of A1S_2006 in AB030 and it is 
because the primer binding sites for the qRT-PCR are present downstream of the insertion 
element, and that the qRT-PCR was detecting the truncated mRNA. However, this finding also 
suggests that A1S_2006 is likely to be an interesting candidate to further characterize in order to 
study its role in antibiotic resistance and virulence of A. baumannii. 
Since both AB030 and AB031 are clinical isolates and prior to this study no information 
was available about their genomes, we decided to sequence both strains in order to characterize 
the TCSs in these strains. Comparative whole-genome analysis is an effective way to understand 
the genetic features that have been acquired, modified, or lost, and helped A. baumannii to 
evolve and adapt to specific environmental niches. Thus, the whole-genome analysis of TCSs in 
the clinical isolates AB030 and AB031 can provide insights about the mechanisms that are 
responsible for their adaptations and pathogenesis. Our data revealed the presence of fifteen 
TCSs genes clusters, these clusters were found to be common between AB030 and AB031 and 
ATCC17978, and the TCSs cluster A1S_2937_38 was absent from AB030 and AB031. Two 
more TCSs gene clusters were identified AB57_2542_43 and AB57_2550_51 and these two 
TCSs were only common between a previously sequenced bloodstream isolate AB0057 (NCBI: 
NC_011586) and AB031. This comparative genomic analysis allowed the identification of a core 
of complete TCSs protein orthologs among these two clinical isolates. The whole-genome 
sequencing analysis of AB030 and AB031 identified point mutations in A1S_2137_38 operon 
(Appendix. 3), A1S_1977_78 operon (Appendix. 4), and A1S_1573_74 operon in AB030 
(Appendix. 2) that could alter the activities of these TCSs in AB030 and AB031. Further 
genomic investigation of these point mutations is important in order to clarify the role of TCSs in 
MDR A. baumannii. 
75 
 
Little is known about TCSs in A. baumannii, and the results obtained during this study 
will be helpful in understanding the multi-drug resistance phenotype in A. baumannii, and 
uncover the essential role of TCSs in regulating antibiotics resistance and virulence in A. 
baumannii.  
4.2 Identification and characterization of the two component system A1S_3229_30. 
 
Expression analysis of TCSs from the clinical isolates AB030 and AB031 observed 
differential expressions of five TCSs response regulators. BLAST search in other bacterial 
species did not show any significant homology for these four genes (A1S_1753_54, 
A1S_1977_78, A1S_2006, and A1S_2137_38), suggesting that these genes are only unique to 
Acinetobacter species. On the other hand, A1S_3229_30 showed 73% identity to the AmgRS 
operon that encodes the characterized AmgRS system of P. aeruginosa as seen in Figure 3.5. 
The TCSs AmgRS in the pathogen P. aeruginosa confers resistance to aminoglycoside 
antibiotics and is required for the virulence of the problematic pathogen P. aeruginosa. 
Screening for small molecules to inhibit AmgRS system is expected to provide the dual benefit 
of compromising infection directly as well as enhancing antibiotic sensitivity (Lee et al., 2009). 
This finding is crucial and supports the idea of identifying a novel TCSs for a new drug 
discovery, this also indicates that A1S_3229_30 system in A. baumannii is an excellent 
candidate for further characterization, since that the sequence of A1S_3229_30 was highly 
conserved among the wild-type ATCC17978, AB030, and AB031. 
4.3 Creation of a gene-knock out of the two component systems operon A1S_3229_30. 
 
Genetic characterization of the A1S_3229-30 system in A. baumannii will require the 
creation of gene knock-out as the first step. One of the challenges with creating knock-outs in A. 
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baumannii in general is the lack of proper genetic tools. In addition to this, creation of knock-
outs in clinical isolates has its own problems because of their high resistance to antibiotics that 
are used to selection. For example, the plasmid pKNG101 (Kaniga et al., 1991), which is widely 
used for creating knock-outs in Gram-negative bacteria, cannot be used in ATCC17978, AB030, 
or AB031 because of their resistance to streptomycin which is the selection marker present on 
this plasmid. In order to investigate of the role A1S_3229_30 a creation of a deletion mutant of 
A1S_3229_30 is essential. Since, there are relatively few proper genetic tools for manipulation of 
chromosomal genes in A. baumannii, construction of two suicide plasmids (trimethoprim-
resistant, pPLS103 and tetracycline-resistant, pPLS109) was carried for allelic replacement in A. 
baumannii. There are various advantages associated with the use of these plasmids; it contains 
multiple cloning sites and the presence of sacB gene that works as a counterselection marker 
enabling the curing of the plasmid (Choi and Schweizer, 2005). 
A gene deletion construct for A1S_3229_30 was prepared using the PCR-based method 
(SOEing) as shown in Figure 2.1. This product was cloned into the suicide vector pPLS103 
(Figure 3.8) to be used as delivery plasmid. However, repeated attempts to delete A1S_3229_30 
in the chromosome of the wild-type strain ATCC17978 were not successful. It is possible that 
the plasmid gets incorporated into another region of the chromosome other than targeted region. 
In addition, the whole genome sequencing showed the presence of aminoglycoside resistance 
gene aac(3)-IIa was detected in the chromosome of AB030, thus explaining the failure to isolate 
conjugants with the plasmid insertion at the desired site of A1S_3229_30. This problem can be 
alleviated by using a different antibiotic resistance marker, for example kanamycin or by using 
an unmarked truncated gene for gene deletion. 
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In summary, the purpose of this study was to identify and characterize TCSs in A. 
baumannii that are likely to act as global regulators of antibiotic resistance and/or virulence. This 
study resulted in the successful cloning of thirteen different TCSs-encoding genes. Using two 
clinical isolates and comparative genomics and transcriptomics, this study was able to identify 
five novel TCSs in A. baumannii that may be involved in regulating virulence and antibiotic 
resistance. Also of interest are A1S_2006, which was found to contain an insertion sequence in 
AB030 but not in AB031. This gene would be a good candidate for further characterization. Also 
of note is the data generated on AdeRS system in combination with the previously published data 
on the expression of AdeABC pump (Marchand et al., 2004), which is regulated by the AdeRS 
system. This study shows that the expression of this efflux pump can be regulated independent of 
the AdeRS system as seen in AB031. Another important candidate identified in this study is the 
A1S_3229_30, a close homolog of the AmgRS system in P. aeruginosa, which is known to 
regulate antibiotic resistance and virulence in this organism. 
While the confirmation of the role of these five TCSs identified in this study can only be 
achieved by creating gene knock-outs, this study also resulted in the creation of new and 


























  The creation of a deletion mutant of A1S_3229_30 is important in order to characterize 
the role of this system by using an alternative strategy to delete A1S_3229_30 operon by 
disrupting the operon with different antibiotic resistance markers such as kanamycin or 
neomycin. This could increase the ability of the construct to recombine into the chromosome, 
and enable for better selection of the single recombination event in both the wild-type strain 
ATCC17978, AB030, and AB031. Followed by expression analysis experiment such as qRT-
PCR to clarify if this system is playing a role in the regulation of RND efflux pumps, porins, or 
if this system is involved in the regulation of characterized virulence factors like OmpA, PhosD. 
Further virulence phenotypic analysis is required such as biofilm formation assay, and motility 
assay. Minimum inhibitory concentration assay using clinical antibiotics such as 
aminoglycosides is essential to determine if the deletion mutant strain of A1S_3229_30 exhibit 
susceptibility phenotype to these drugs.  
 The whole-genome analysis of AB030 observed 3902 bp DNA insertion in length to 
generate AB030 A1S_2006 mutant strain. The full length gene with its native promoter is cloned 
into pGEMT-Easy commercial vector, and the recombinant plasmid is named pPLS105. Cloning 
the full length gene with its own promoter into an A. baumannii overexpression vector and 
introducing it to AB030 to complement the A1S_2006 mutant in AB030 is an interesting 
experiment. Followed by phenotypic experiments such as MIC and qRT-PCR, biofilm formation 
assay, this possibly can give a better insight of the role of A1S_2006 in AB030 MDR phenotype.  
 Furthermore, AB030 and AB031 also provide an excellent model to understand 
seemingly complex regulation of the AdeABC pump. Since, AB031 overexpresses the AdeABC 
pump in spite of an insertion element in the adeR gene, it would be interesting to complement the 
AB031 strain with the intact copy of the adeRS genes in order to determine the extent of role 
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AdeRS system plays in the overexpression of the AdeABC pump. Similarly, deletion of the 
AdeRS system in AB030 will show whether the overexpression of the AdeABC system in this 
strain solely due to the activity of the AdeRS system.  
To summarize, more research is required in order to understand the global mechanisms of 
TCSs in the regulation of MDR and virulence phenotypes. All this information is essential to 
understand and resolve the role of TCSs in increasing resistance and virulence in MDR A. 
baumannii. This research has provided exciting results to understand the role of TCSs in A. 
baumannii, nevertheless more research is required before this information can be interpreted into 
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Appendix 1. Amino acids alignment of BfmRS in A. baumannii ATCC17978, AB030, and 
AB031.   
 
   AB030           MLPGADGLTVCREVRPHYHQPILMLTARTEDMDQVLGLEMGADDYVAKPVQPRVLLARIR 60 
AB031           MLPGADGLTVCREVRPHYHQPILMLTARTEDMDQVLGLEMGADDYVAKPVQPRVLLARIR 60 
ATCC17978       MLPGADGLTVCREVRPHYHQPILMLTARTEDMDQVLGLEMGADDYVAKPVQPRVLLARIR 60 
                ************************************************************ 
 
AB030           ALLRRTDKTVEDEVAQRIEFDDLVIDNGGRSVTLNGELVDFTSAEYDLLWLLASNAGRIL 120 
AB031           ALLRRTDKTVEDEVAQRIEFDDLVIDNGGRSVTLNGELVDFTSAEYDLLWLLASNAGRIL 120 
ATCC17978       ALLRRTDKTVEDEVAQRIEFDDLVIDNGGRSVTLNGELVDFTSAEYDLLWLLASNAGRIL 120 
                ************************************************************ 
 
AB030           SREDIFERLRGIEYDGQDRSIDVRISRIRPKIGDDPENPKRIKTVRSKGYLFVKETNGLM 180 
AB031           SREDIFERLRGIEYDGQDRSIDVRISRIRPKIGDDPENPKRIKTVRSKGYLFVKETNGLM 180 
ATCC17978       SREDIFERLRGIEYDGQDRSIDVRISRIRPKIGDDPENPKRIKTVRSKGYLFVKETNGLM 180 
                ************************************************************ 
 
AB030           KALPIFVLDYLMFYPGQEQEYLAKIQKHFSYPINIQNIQDVNLDSEQIGRLRQDQSVMLY 240 
AB031           KALPIFVLDYLMFYPGQEQEYLAKIQKHFSYPINIQNIQDVNLDSEQIGRLRQDQSVMLY 240 
ATCC17978       KALPIFVLDYLMFYPGQEQEYLAKIQKHFSYPINIQNIQDVNLDSEQIGRLRQDQSVMLY 240 
                ************************************************************ 
 
AB030           KDSATVRGTTISIVSPIPNHPAQVLVLGPVPMFNWMPLQLSAGITLFSLFLLSLGVYGLI 300 
AB031           KDSATVRGTTISIVSPIPNHPAQVLVLGPVPMFNWMPLQLSAGITLFSLFLLSLGVYGLI 300 
ATCC17978       KDSATVRGTTISIVSPIPNHPAQVLVLGPVPMFNWMPLQLSAGITLFSLFLLSLGVYGLI 300 
                ************************************************************ 
 
AB030           LPLERKIRQVRYALNRMKSGDLSLRVPIEGSDEMANLASSYNNMSDHIQRLIEAQRELMR 360 
AB031           LPLERKIRQVRYALNRMKSGDLSLRVPIEGSDEMANLASSYNNMSDHIQRLIEAQRELMR 360 
ATCC17978       LPLERKIRQVRYALNRMKSGDLSLRVPIEGSDEMANLASSYNNMSDHIQRLIEAQRELMR 360 
                ************************************************************ 
 
AB030           AVSHELRTPVARIRFGTEMLAEEDDYNHRMHQVDMIDKDIEALNTLIDEIMTYAKLEQGT 420 
AB031           AVSHELRTPVARIRFGTEMLAEEDDYNHRMHQVDMIDKDIEALNTLIDEIMTYAKLEQGT 420 
ATCC17978       AVSHELRTPVARIRFGTEMLAEEDDYNHRMHQVDMIDKDIEALNTLIDEIMTYAKLEQGT 420 
                ************************************************************ 
 
AB030           PSLDFAEIVLFEVLDQVAVETEALKTQKEIELIPPPLYVKVDAERRYLHRVVQNLVGNAV 480 
AB031           PSLDFAEIVLFEVLDQVAVETEALKTQKEIELIPPPLYVKVDAERRYLHRVVQNLVGNAV 480 
ATCC17978       PSLDFAEIVLFEVLDQVAVETEALKTQKEIELIPPPLYVKVDAERRYLHRVVQNLVGNAV 480 
                ************************************************************ 
 
AB030           RYCDNKVRITGGIHSDGMAFVCVEDDGPGIPEQDRKRVFEAFARLDDSRTRASGGYGLGL 540 
AB031           RYCDNKVRITGGIHSDGMAFVCVEDDGPGIPEQDRKRVFEAFARLDDSRTRASGGYGLGL 540 
ATCC17978       RYCDNKVRITGGIHSDGMAFVCVEDDGPGIPEQDRKRVFEAFARLDDSRTRASGGYGLGL 540 
                ************************************************************ 
 
AB030           SIVSRIAYWFGGEIKVDESPSLGGARFIMTWPAHRFKQPPLKTNKKAPA 589 
AB031           SIVSRIAYWFGGEIKVDESPSLGGARFIMTWPAHRFKQPPLKTNKKAPA 589 
ATCC17978       SIVSRIAYWFGGEIKVDESPSLGGARFIMTWPAHRFKQPPLKTNKKAPA 589 
                ************************************************* 
 
(-) Extra residues.  
(*) Identical residue  
(:) Strongly similar residue (scoring >0.5 in the Gonnet PAM matrix) 
(.) Weakly similar residue (scoring <0.5 in the Gonnet PAM matrix) 
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Appendix 2. Amino acids alignment of AdeRS in A. baumannii ATCC17978 and AB030. 
 
ATCC17978       MSVIRAMNGKQAIELHASQPIDLILLDIKLPELNGWEVLNKIRQKAQTPVIMLTALDQDI 60 
AB030           MSVIRAMNGKQAIELHASQPIDLILLDIKLPELNGWEVLNKIRQKAQTPVIMLTALDQDI 60 
                ************************************************************ 
 
ATCC17978       DKVMALRIGADDFVVKPFNPNEVVARVQAVLRRTQFANKATNKNKLYKNIEIDTDTHSVY 120 
AB030           DKVMALRIGADDFVVKPFNPNEVIARVQAVLRRTQFANKATNKNKIYKNIEIDTDTHSVY 120 
                ***********************:*********************:************** 
 
ATCC17978       IHSENKKILLNLTLTEYKIISFMIDQPHKVFTRGELMNHCMNDSDALERTVDSHVSKLRK 180 
AB030           IHSENKKILLNLTLTEYKIISFMIDQPHKVFTRGELMNHCMNDSDALERTVDSHVSKLRK 180 
                ************************************************************ 
 
ATCC17978       KLEEQGIFQMLINVRGVGYRLDNPLAVKDDAMRLAKRFIVPINFLAEAAKKISHGDLSAR 240 
AB030           KLEEQGIFQMLINVRGVGYRLDNPLAVKDDAMRLAKRFIVPINFLAEAAKKISHGDLSAR 240 
                ************************************************************ 
 
ATCC17978       AYDNRIHSAEMSELLYNFNDMAQKLEVSVKNAQVWNAAIAHELRTPITILQGRLQGIIDG 300 
AB030           AYDNRIHSAEMSELLYKFNDMAQKLEVSVKNAQVWNAAIAHELRTPITILQGRLQGIIDG 300 
                ****************:******************************************* 
 
ATCC17978       VFKLDEVLFKSLLNQVEGLSHLVEDLRTLSLVENQQLRLNYELFDFKAVVEKVLKAFEDR 360 
AB030           VFKPDEVLFKSLLNQVEGLSHLVEDLRTLSLVENQQLRLNYELFDFKAVVEKVLKAFEDR 360 
                *** ******************************************************** 
 
ATCC17978       LDQAKLVPELDLTSTPVYCDRRRIEQVLIALIDNAIRYSNAGKLKISSEVVSQNWILKIE 420 
AB030           LDQAKLVPELDLTSTPVYCDRRRIEQVLIALIDNAIRYSNAGKLKISSEVVSQNWILKIE 420 
                ************************************************************ 
 
ATCC17978       DEGPGIATEFQDDLYKPFFRLEESRNKEFGGTGLGLAVVHAIIVALKGTIQYSNQGSKSV 480 
AB030           DEGPGIATEFQDDLFKPFFRLEESRNKEFGGTGLGLAVVHAIVVALKSTIQYSNQGSKSI 480 
                **************:***************************:****.***********: 
 
ATCC17978       FTIKISMGHEEIG 493 
AB030           FTIKISM------ 487 
                *******       
(-) Extra residues.  
(*) Identical residue  
(:) Strongly similar residue (scoring >0.5 in the Gonnet PAM matrix) 










Appendix 3. Amino acids alignment of A1S_2137_38 in A. baumannii ATCC17978, AB030, 
and AB031. 
 
ATCC17978       MTKPFSVQELLARIRVILRNQPIQQEAHIYDDGYLKVDVTQRLVWIEQQPITLTRKEFQL 60 
AB030           MTKPFSVQELLARIRVILRNQPIQQEAHVYDDGYLKVDVTQRLLWVEQQPITLTRKEFQL 60 
AB031           MTKPFSVQELLARIRVILRNQPIQQEAHIYDDGYLKVDVTQRLVWIEQQPITLTRKEFQL 60 
                ****************************:**************:*:************** 
 
ATCC17978       LALLMRYQGQLLTQPQLLKELWGPTHQEDTHYLRILVGKLRSKLGDNAIQPRYIATEPGV 120 
AB030           LTLLMRYQGQLLTQPQLLKELWGPTHQEDTHYLRILVGKLRSKLGDNAIQPRYIATEPGV 120 
AB031           LTLLMRYQGQLLTQPQLLKELWGPTHQEDTHYLRILVGKLRSKLGDNAIQPRYIATEPGV 120 
                *:********************************************************** 
 
ATCC17978       GLRFLAKQKNHMLARAKELYQQGTDVVVGIVETHGRIETLKILEGLPQIARKEMQYQGHT 180 
AB030           GLRFLAKQKNHMLARAKELFQQGTDVVVGIVETHGRIETLKILEGLPQIARKEMQYQGHT 180 
AB031           GLRFLAKQKNHMLARAKELFQQGTDVVVGIVETHGRIETLKILEGLPQIARKEMQYQGHT 180 
                *******************:**************************************** 
 
ATCC17978       LEEMDLDAILLRHPQIVLVDELAHRNVPNSRHERRWQDVNELLDAGIDVFTTINIQHLES 240 
AB030           LEEMDLDAILLRHPQIVLVDELAHRNVPNSRHERRWQDVNELLDAGIDVFTTINIQHLES 240 
AB031           LEEMDFDAILLRHPEIVLVDELAHRNIPNSRHERRWQDVNELLDAGIDVFTTINIQHLES 240 
                *****:********:***********:********************************* 
 
ATCC17978       LNDVVYQITGIRVNETVPDRVFDRIRDIRLIDLPVSELIERLHQGKVYVPEQANLALQGF 300 
AB030           LNDVVYQITGIRVNETVPDRVFDRIRDIRLIDLPVSELIERLHQGKVYVPEQANLALQGF 300 
AB031           LNDVVHQITGIRVNETVPDRVFDRIRDIRLIDLPVSELIERLHQGKVYVPEQANLALQGF 300 
                *****:****************************************************** 
 
ATCC17978       FSISNLTALRELAMQCVAEHVDSDLKESYASKGLKSISLQNELMIAIDGQGSSEYLVRAG 360 
AB030           FSISNLTALRELAMQCVAEHVDSDLKESYASKGLKSISLQNELMIAIDGQGSSEYLVRAG 360 
AB031           FSISNLTALRELAMQCVAEHVDSDLKESYASKGLKSISLQNELMIAIDGQGSSEYLVRAG 360 
                ************************************************************ 
 
ATCC17978       CRLAERNGATWTVVNVAKSLDFGQSSVSSYKKEYIEIDRAFELARQLGGRTEVLYGPRVA 420 
AB030           CRLAERNGATWTVVNVAKSLDFGQSSVSSSKKEYIEIDRAFELARQLGGRTEVLYGPRVA 420 
AB031           CRLAERYGATWTVVNVAKSLDFGQSSRNSYKKEYIEIDRAFELARQLGGRTEVLYGHQVA 420 
                ****** ******************* .* ************************** :** 
 
ATCC17978       SVLMDAAVDRGISNLVIGKSISPWWLKLFKKNLAQQLLNQENSIALTILHPEQGTKKINQ 480 
AB030           SVLMDAAVDRGISNLVIGKSISPWWLKLFKKNLAQQLLNQENSIALTILHPEQGTKKINQ 480 
AB031           SVLMDAAVDRGISNLVIGKSISPWWLKLFKKNLAQQLLNQENSIALTILHPEQRTKKINQ 480 
                ***************************************************** ****** 
 
ATCC17978       LKKPSFLSLKESVFVLAVTCGSIFIAHFAEVLFGIEDFSVIFIISVLIVATKTRMLAAVV 540 
AB030           LKKPSFLSLKESVFVLAVTCGSIFLAHFAEVLFGIEDFSVIFIISVLIVATKTRMLAAVV 540 
AB031           LEKPSFLSLKESVFVLAVTCASIFIAHFAEVLFGIEDFSVIFIISVLIVATKTRMLAAVV 540 
                *:******************.***:*********************************** 
 
ATCC17978       AALICFLAYNFFFIAPRYTFQISAHQGVVTVVAFFAAALIAGRLASQLRQQVLSLKAANA 600 
AB030           AALICFLAYNFFFIAPRYTFQISAHQGVVTVVAFFAAALIAGRLASQLRQQVLSLKAANA 600 
AB031           AALICFLAYNFFFIAPRYTFQISAHQGVVTVVAFFAAALIAGRLASQLRQQVLSLKAANA 600 
                ************************************************************ 
 
ATCC17978       YTTVMQDLARKLSSAVNLEEVMQTGRMTLETQLQTKVWISIRDKIISSDIELNDKEKVAA 660 
AB030           YTMVMQDLARKLSSAVNLEEVMQTGRMTLETQLQTKVWISIRDKVISSDIELNDKEKVAA 660 
AB031           YTTVMQDLARKLSSAVNLEEVMQTGRMTLETQLQTKVWISIQDKVISSDIELNDKEKVAA 660 
                ** **************************************:**:*************** 
 
ATCC17978       EWCLKHQQPCGRFTDTLSQSNWWFLPLLEQKNSLGIVGIYFKDEVVSLNFEQKKLTESVI 720 
AB030           EWCLKHKQPCGRFTDTLSQSNWWFLPLLEQKNSLGIVGIYFKDEVVSLNFEQKKLTESVI 720 
AB031           EWCLKHKQPCGRFTDTLSQSNWWFLPLLEQKNSLGIVGIYFKDEVVSLNFEQKKLTESVI 720 
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                ******:***************************************************** 
 
ATCC17978       EYIAQAALRTQLVNELEQAKVTSETERLRSALLSSVSHDLRSPLASIIGAADTLANFKAE 780 
AB030           EYIAQAVLRTQLVNELEQAKVTSETERLRSALLSSVSHDLRSPLASIIGAADTLANFKAE 780 
AB031           EYIAQAVLRTQLVNELEQAKVTSETERLRSALLSSVSHDLRSPLASIIGVADTLANFKAE 780 
                ******.******************************************.********** 
 
ATCC17978       MTEQDQQDLLETIHLEGERLDRYIQNLLDMTRLGHEGLTLKRDWIGVDELIGSATRRLKR 840 
AB030           MTEQDQQDLLETIHLEGERLDRYIQNLLDMTRLGHEGLTLKRDWIGVDELIGSATRRLKR 840 
AB031           MSEQDQQDLLETIHLEGERLDRYIQNLLDMTRLGHEGLTLKRDWIGVDELIGSATRRLKR 840 
                *:********************************************************** 
 
ATCC17978       YKPDTQVVVQLPEQPISLYVHPALVEQAIFNVLENAANFSPPDESVMIRAQLLSEDEVKI 900 
AB030           YKPDTQVVVQLSEQPISLYVHPALVEQAIFNVLENAANFSPPDEPVMIRTHLVSEDEVKI 900 
AB031           YKPDTQVAVQLPEQPISLYVHPALVEQAIFNVLENAANFSPPDEPVMIRTHLVSEDEVKI 900 
                *******.***.********************************.****::*:******* 
 
ATCC17978       EIEDKGVGIPEDERHRIFDMFYTMERGDRGKFGTGLGLTIVKAIIGAHMGTIEAFSGRQN 960 
AB030           EIEDKGAGIPEDERHRIFDMFYTMERGDRGKFGTGLGLTIVKAIIGAHMGTIEAFSGCQN 960 
AB031           EIEDKGVGIPEDERHRIFDMFYTMERGDRGKFGTGLGLTIVKAIIGAHRGTIEAFSGRQN 960 
                ******.***************************************** ******** ** 
 
ATCC17978       KGTLIQIKLPLRPVKE 976 
AB030           KGTLIQIKLPLHPVKE 976 
AB031           KGTLIQIKLPLHPVKE 976 
                ***********:**** 
 
(-) Extra residues.  
(*) Identical residue  
(:) Strongly similar residue (scoring >0.5 in the Gonnet PAM matrix) 








AB030           MLKISKEENLIQQHQVARQLVRGVAHEIKNPLAGIRGATQLLARSLNDESYAEFTDIIIN 60 
AB031           MLKISKEENLIQQHQVARQLVRGVAHEIKNPLAGIRGATQLLARSLNDESYAEFTDIIIN 60 
ATCC17978       MLKISKEENLIQQHQVARQLVRGVAHEIKNPLAGIRGATQLLARSLNDESYAEFTDIIIN 60 
                ************************************************************ 
 
AB030           EVDRLTNLADTMLGSRQLPSYENVNVHEPLERVRSLIANQTKKKIKITRDYDLSLPDVKA 120 
AB031           EVDRLTNLADTMLGSRQLPSYENVNVHEPLERVRSLIANQTKKKIKITRDYDLSLPDVKA 120 
ATCC17978       EVDRLTNLADTMLGSRQLPSYENVNVHEPLERVRSLIANQTKKKIKITRDYDLSLPDVKA 120 
                ************************************************************ 
 
AB030           DRDQLIQVMLNISVNAIQAITENKSFFTDQEPELILRTRIQRLVTINGVLNRSAVRVDIE 180 
AB031           DRDQLIQVMLNISVNAIQAITENKSFFTDQEPELILRTRIQRLVTINGVLNRSAVRVDIE 180 
ATCC17978       DRDQLIQVMLNISVNAIQAITENKSFFTDQEPELILRTRIQRLVTINGVLNRSAVRVDIE 180 
                ************************************************************ 
 
AB030           DNGPGIPESILESVFYPLVTGRAKGTGLGLSIAQNIMHQHNGMIECQSVPGKTMFSLYLP 240 
AB031           DNGPGIPESILESVFYPLVTGRAKGTGLGLSIAQNIMHQHNGMIECQSVPGKTMFSLYLP 240 
ATCC17978       DNGPGIPESILESVFYPLVTGRAKGTGLGLSIAQNIMHQHNGMIECQSVPGKTMFSLYLP 240 
                ************************************************************ 
 
AB030           WESDRVAKMRWVLEKTFKEEGFDVTNFEEAQTALERLHHDAPDVILTDIRMPGIDGLTFL 300 
AB031           WESDRVAKMRWVLEKTFKEEGFDVTNFEEAQTALERLHHDAPDVILTDIRMPGIDGLTFL 300 
ATCC17978       WESDRVAKMRWVLEKTFKEEGFDVTNFEEAQTALERLHHDAPDVILTDIRMPGIDGLTFL 300 
                ************************************************************ 
 
AB030           SKVKNSHPDLPVIIMTAHSDLESAVSSYQTGAFEYLPKPFDIDEALALVNRAILHINKLQ 360 
AB031           SKVKNSHPDLPVIIMTAHSDLESAVSSYQTGAFEYLPKPFDIDEALALVNRAILHINKLQ 360 
ATCC17978       SKVKNSHPDLPVIIMTAHSDLESAVSSYQTGAFEYLPKPFDIDEALALVNRAILHINKLQ 360 
                ************************************************************ 
 
AB030           QQEATKTASPLQSTEIIGESPAMQEVFRAIGRLSQSHITVLINGESGTGKELVAHALHKH 420 
AB031           QQEATKTASPLQSTEIIGESPAMQEVFRAIGRLSQSHITVLINGESGTGKELVAHALHKH 420 
ATCC17978       QQEATKTASPLQSTEIIGESPAMQEVFRAIGRLSQSHITVLINGESGTGKELVAHALHKH 420 
                ************************************************************ 
 
AB030           SPRRAKPFIALNMAAIPKDLIETELFGHEKGAFTGANTQHQGRFEQANGGTLFLDEIGDM 480 
AB031           SPRRAKPFIALNMAAIPKDLIETELFGHEKGAFTGANTQHQGRFEQANGGTLFLDEIGDM 480 
ATCC17978       SPRRAKPFIALNMAAIPKDLIETELFGHEKGAFTGANTQHQGRFEQANGGTLFLDEIGDM 480 
                ************************************************************ 
 
AB030           PFETQTRLLRVLADGEFYRVGGHIPVKVDVRIVAATHQDLEKLVNEGRFREDLYHRLNVI 540 
AB031           PFETQTRLLRVLADGEFYRVGGHIPVKVDVRIVAATHQDLEKLVNEGRFREDLYHRLNVI 540 
ATCC17978       PFETQTRLLRVLADGEFYRVGGHIPVKVDVRIVAATHQDLEKLVNEGRFREDLYHRLNVI 540 
                ************************************************************ 
 
AB030           RIHIPKLAHRSEDIPMLAQHFLARAGKELGVSPKILHTETTDYMQQLPWPGNVRQLENTC 600 
AB031           RIHIPKLAHRSEDIPMLAQHFLARAGKELGVSPKILRTETTDYMQQLPWPGNVRQLENTC 600 
ATCC17978       RIHIPKLAHRSEDIPMLAQHFLARAGKELGVSPKILRTETTDYMQQLPWPGNVRQLENTC 600 
                ************************************:*********************** 
 
AB030           RWLTVMITGREVYPEDLPSELKQVPLQKSSETSQPAPSFERISLHHWDELLSQWAIQKLK 660 
AB031           RWLTVMITGREVYPEDLPSELKQVPLQKSSETSQPAPSFERISLHHWDELLSQWAIQKLK 660 
ATCC17978       RWLTVMITGREVYPEDLPSELKQVPLQKSSETSQPTPSFERISLHHWDELLSQWAIQKLK 660 
 




AB030           NGEMKILDIATPMFERTLINAALQQTRGRKRHAAELLGWGRNTLTRKLKELGMDSADDDD 720 
AB031           NGEMKILDIATPMFERTLINAALQQTRGRKRHAAELLGWGRNTLTRKLKELGMDSADDDD 720 
ATCC17978       NGEMKILDIATPMFERTLINAALQQTRGRKRHAAELLGWGRNTLTRKLKELGMDSADDDD 720 
                ************************************************************ 
 
AB030           EDEHKATLSEA 731 
AB031           EDEHKATLSEA 731 
ATCC17978       EDEHKATLSEA 731 
                *********** 
 
(-) Extra residues.  
(*) Identical residue  
(:) Strongly similar residue (scoring >0.5 in the Gonnet PAM matrix) 






Appendix 5. Nucleotide alignments of A1S_2006 in A. baumannii ATCC17978, andAB030. 
The nucleotides underlined indicates the sequence of the additional DNA insertion in 
AB030. 
 
17978           ATGGATCATCCCCATCGTGACATTATTGAAAGTTGTGTGAGTAGCTATGACCTACCAACT 60 
AB030           ATGGATCATCCCCATCGTGACATTATTGAAAGTTGTGTGAGTAGCTATGACCTACCAACT 60 
                ************************************************************ 
 
17978           GTTCTATTCACTAAAAATTCAGATAAAGACACCATCAAACAAGCTATAGATGCAGGCGTA 120 
AB030           GTTCTATTCACTAAAAATTCAGATAAAGACACCATCAAACAAGCTATAGATGCAGGCGTA 120 
                ************************************************************ 
 
17978           ACGGCTTATATTGTAGATGGCATAGACCCCGCCCGCTTACATACCATTTTAGAGATTTCA 180 
AB030           ACGGCTTATATTGTAGATGGCATAGACCCCGCTCGCTTACATACCATTTTAGAGATTTCA 180 
                ******************************** *************************** 
 
17978           ATTGAGCAATATAAAAAACAT--------------------------------------- 201 
AB030           ATTGAGCAATATAAAAAACATCTCTGTACACGACAAATTTCACAGAACCCTTATCCTATC 240 
                *********************                                        
 
17978           ------------------------------------------------------------ 
AB030           AGGATTCTGCCTTCTTAAAATGACACATCTCAATGAGTTATATCTTATCTTAAACAAATC 300 
                                                                             
 
17978           ------------------------------------------------------------ 
AB030           TCTAAAATGGAACAAGTCACATTTAAAGTGCTTTGCGCTCATCATGCTTGTGATTATTTT 360 
                                                                             
 
17978           ------------------------------------------------------------ 
AB030           AAAGCAAACATGTAATCTTTCTTCTGCATCTAAAGCCTTGCCCATCAAGTGCTTACCACA 420 
                                                                             
 
17978           ------------------------------------------------------------ 
AB030           ATCATTTTATCGACGTATGCAGCGCTTCTTTGCAGGTCAGTATTTTGATTATCGTCAAAT 480 
                                                                             
 
17978           ------------------------------------------------------------ 
AB030           TTCTCAGTTGATTTTCAATATGTTTTCATTCGACCAAGTGCAACTGACTTTAGATAGAAC 540 
                                                                             
 
17978           ------------------------------------------------------------ 
AB030           CAATTGGAAATGGGGAAAACGAAATATTAATATCCTGATGCTCGCAATCGTTTATCGTGG 600 
                                                                             
 
17978           ------------------------------------------------------------ 
AB030           AATAGCGATACCTATCCTTTGGACATTGCTTAATAAACGTGGAAATTCAGATACGAAAGA 660 
                                                                             
 
17978           ------------------------------------------------------------ 
AB030           GCGCATTGCTTTGATTCAACGCTTTATAGCCATTTTTGGTAAAGACCGTATTGTGAATGT 720 
                                                                             
 
17978           ------------------------------------------------------------ 
AB030           GTTCGCAGACAGAGAGTTTATCGGTGAGCAGTGGTTTACATGGTTAATTGAACAAGACAT 780 




17978           ------------------------------------------------------------ 
AB030           CAACTTCTGCATTCGTGTTAAAAAAACTTCATTGTCACCAATCATTTAGATGAATAAATA 840 
                                                                             
 
17978           ------------------------------------------------------------ 
AB030           TTTTACTTGCTATGTGGTTGCTTCTCTTTTTCTTTCTGGTTGTACGGTTCAGCATAATTT 900 
                                                                             
 
17978           ------------------------------------------------------------ 
AB030           AATAAATGAAACCCCGAGTCAGATTGTTCAAGGACATAATCAGGTGATTCATCAATACTT 960 
                                                                             
 
17978           ------------------------------------------------------------ 
AB030           TGATGAAAAAAACACCTCAGGTGTGCTGGTTATTCAAACAGATAAAAAAATTAATCTATA 1020 
                                                                             
 
17978           ------------------------------------------------------------ 
AB030           TGGTAATGCTCTAAGCCGCGCAAATACAGAATATGTGCCAGCCTCTACATTTAAAATGTT 1080 
                                                                             
 
17978           ------------------------------------------------------------ 
AB030           GAATGCCCTGATCGGATTGGAGAACCAGAAAACGGATATTAATGAAATATTTAAATGGAA 1140 
                                                                             
 
17978           ------------------------------------------------------------ 
AB030           GGGCGAGAAAAGGTCATTTACCGCTTGGGAAAAAGACATGACACTAGGAGAAGCCATGAA 1200 
                                                                             
 
17978           ------------------------------------------------------------ 
AB030           GCTTTCTGCAGTCCCAGTCTATCAGGAACTTGCGCGACGTATCGGTCTTGATCTCATGCA 1260 
                                                                             
 
17978           ------------------------------------------------------------ 
AB030           AAAAGAAGTAAAACGTATTGGTTTCGGTAATGCTGAAATTGGACAGCAGGTTGATAATTT 1320 
                                                                             
 
17978           ------------------------------------------------------------ 
AB030           CTGGTTGGTAGGACCATTAAAGGTTACGCCTATTCAAGAGGTAGAGTTTGTTTCCCAATT 1380 
                                                                             
 
17978           ------------------------------------------------------------ 
AB030           AGCACATACACAGCTTCCATTTAGTGAAAAAGTGCAGGCTAATGTAAAAAATATGCTTCT 1440 
                                                                             
 
17978           ------------------------------------------------------------ 
AB030           TTTAGAAGAGAGTAATGGCTACAAAATTTTTGGAAAGACTGGTTGGGCAATGGATATAAA 1500 
                                                                             
 
17978           ------------------------------------------------------------ 
AB030           ACCACAAGTGGGCTGGTTGACCGGCTGGGTTGAGCAGCCAGATGGAAAAATTGTCGCTTT 1560 
                                                                             
 
17978           ------------------------------------------------------------ 
AB030           TGCATTAAATATGGAAATGCGGTCAGAAATGCCGGCATCTATACGTAATGAATTATTGAT 1620 
                                                                             
 
17978           ------------------------------------------------------------ 
AB030           GAAATCATTAAAACAGCTGAATATTATTTAAATGCAAATAACTCTAGAAATCAAATGTCC 1680 
                                                                             
 
17978           ------------------------------------------------------------ 
AB030           AACCTGCCTCAGTGACAGTATAAAGAAAAATGGCATCAAAGTAGATGGGAAACAAAACTA 1740 




17978           ------------------------------------------------------------ 
AB030           CCAATGCAAAGACTGCAAACGTCAGTTTATTGGTGACCATGCTCTGAGCTATCTAGGATG 1800 
                                                                             
 
17978           ------------------------------------------------------------ 
AB030           TAATTCTGGCATTACTCGTAAAATATTACAGTTAATGGTCAGAGGCAGCGGTATACGAGA 1860 
                                                                             
 
17978           ------------------------------------------------------------ 
AB030           TATCGCTGAAGTTGAGCGCATTAGTATCGGTAAAGTCTTACGGACTTTAACTGAATCGGC 1920 
                                                                             
 
17978           ------------------------------------------------------------ 
AB030           CTATCAAATTCAGCCTAAACAAAGTCATTATGAATCTCTCGAAGTAGATGAATTCTGGAC 1980 
                                                                             
 
17978           ------------------------------------------------------------ 
AB030           TTTTGTTGGAAATAAAAATAATAAACAATGGCTTATTTACGCCTACCATCGAGAAACAGG 2040 
                                                                             
 
17978           ------------------------------------------------------------ 
AB030           TGAGATTGTTGCTTATGTTTGGGGTAAGAGAGATTTAGCTACAGTCCAAAGGTTGAAGAC 2100 
                                                                             
 
17978           ------------------------------------------------------------ 
AB030           AAAGCTTAAACAATTAGGTATTCACTACACCCGAATTGCAAGTGATCATTGGGACAGTTT 2160 
                                                                             
 
17978           ------------------------------------------------------------ 
AB030           CATCACTGCTTTTCTCTGTACACGACAAATTTCACAGAACCCTTATCCTATCAGGATTCT 2220 
                                                                             
 
17978           ------------------------------------------------------------ 
AB030           GCCTTCTTAAATGACACATCTCAATGAGTTATATCTTATCTTAAACAAATCTCTAAAATG 2280 
                                                                             
 
17978           ------------------------------------------------------------ 
AB030           GAACAAGTCACATTTAAAGTGCTTTGCGCTCATCATGCTTGTGATTATTTTAAAGCAAAC 2340 
                                                                             
 
17978           ------------------------------------------------------------ 
AB030           ATGTAATCTTTCTTCTGCATCTAAAGCCTTGCCCATCAAGTGCTTACCACAATCATTTTA 2400 
                                                                             
 
17978           ------------------------------------------------------------ 
AB030           TCGACGTATGCAGCGCTTCTTTGCAGGTCAGTATTTTGATTATCGTCAAATTTCTCAGTT 2460 
                                                                             
 
17978           ------------------------------------------------------------ 
AB030           GATTTTCAATATGTTTTCATTCGACCAAGTGCAACTGACTTTAGATAGAACCAATTGGAA 2520 
                                                                             
 
17978           ------------------------------------------------------------ 
AB030           ATGGGGAAAACGAAATATTAATATCCTGATGCTCGCAATCGTTTATCGTGGAATAGCGAT 2580 
                                                                             
 
17978           ------------------------------------------------------------ 
AB030           ACCTATCCTTTGGACATTGCTTAATAAACGTGGAAATTCAGATACGAAAGAGCGCATTGC 2640 
                                                                             
 
17978           ------------------------------------------------------------ 
AB030           TTTGATTCAACGCTTTATAGCCATTTTTGGTAAAGACCGTATTGTGAATGTGTTCGCAGA 2700 
102 
 
                                                                             
 
17978           ------------------------------------------------------------ 
AB030           CAGAGAGTTTATCGGTGAGCAGTGGTTTACATGGTTAATTGAACAAGACATCAACTTCTG 2760 
                                                                             
 
17978           ------------------------------------------------------------ 
AB030           CATTCGTGTTAAAAAAACTTCATTGTCACCAATCATTTAGATGAGTTATCTATTTTTGTC 2820 
                                                                             
 
17978           -------------------AAAAAGCTCGAAGGTGACTTAAAAGAAGCTCAAACCAAACT 242 
AB030           GTGTACAGAGAAAAAACATAAAAAGCTCGAAGGTGACTTAAAAGAAGCTCAAACCAAACT 2880 
                                   ***************************************** 
 
17978           GGCAGACCGTAAAGATGTTGAAAAGGCCAAAGTGCTACTCATGCAACTGCATGGTTTACC 302 
AB030           GGCAGATCGTAAAGATGTTGAAAAGGCCAAAGTGCTACTCATGCAACTGCATGGCTTACC 2940 
                ****** *********************************************** ***** 
 
17978           TGAAGACACAGCTTTTCAATTACTCAGAAAAAATGCCATGAGTCACCGTATAACGATTGG 362 
AB030           TGAAGACACAGCTTTTCAATTACTCAGAAAAAATGCCATGAGTCACCGTATAACGATTGG 3000 
                ************************************************************ 
 
17978           AGAAATGGCACGGCGTTTACTTGACGCTCAAAAATTACTAAATGATCAACTAAAGGATGA 422 
AB030           AGAAATGGCACGGCGTTTACTTGACGCTCAAAAATTACTAAATGATCAACTAAAGGATGA 3060 
                ************************************************************ 
 
17978           ATAA 426 
AB030           ATAA 3064 




Appendix 6. Nucleotide alignment of A1S_1754 in A. baumannii ATCC17978, andAB031. 
The nucleotides underlined indicates the sequence of the additional DNA insertion in 
AB031. 
 
AB031           ATGAGTGTTATTCGGGCCATGAATGGAAAGCAAGCGATTGAATTGCACGCTAGCCAACCC 60 
17978           ATGAGTGTTATTCGGGCCATGAATGGAAAGCAAGCAATTGAATTGCATGCGAGCCAACCC 60 
                *********************************** *********** ** ********* 
 
AB031           ATCGATTTAATCTTACTTGATATTAAATTACCCGAATTAAACGGTTGGGAAGTATTAAAT 120 
17978           ATCGATTTAATCTTACTTGATATTAAATTACCCGAATTAAACGGTTGGGAAGTGTTAAAT 120 
                ***************************************************** ****** 
 
AB031           AAAATACGCCAAAAAGCTCAGACTCCCGTGATCATGTTGACGGCGCTAGATCAAGATATT 180 
17978           AAAATACGCCAAAAAGCTCAGACTCCCGTGATCATGTTGACGGCGTTAGATCAAGATATT 180 
                ********************************************* ************** 
 
AB031           GATAAAGTTATGGCATTACGCATAGGTGCAGATGACTTTGTGGTGAAGCCTTTTAACCCA 240 
17978           GATAAAGTTATGGCATTACGCATAGGTGCAGATGACTTTGTGGTGAAGCCTTTTAACCCA 240 
                ************************************************************ 
 
AB031           AATGAAGTCATCGCTAGAGTTCAGGCAGTCTTAAGACGTACTCAGTTTGCAAACAAGGCA 300 
17978           AATGAAGTCGTCGCTAGAGTTCAGGCAGTCTTAAGACGTACTCAGTTTGCAAACAAAGCA 300 
                ********* ********************************************** *** 
 
AB031           GCTAATAAAAATAAACTCTATAAAAATATTGAAATTGATACCGACACTCATAGCGTTTAT 360 
17978           ACTAATAAAAATAAACTCTATAAAAATATTGAAATTGATACCGACACTCATAGCGTTTAT 360 
                 *********************************************************** 
 
AB031           ATACTCTCAGAGAACAAGAAGATCTTGCTTAATCTGACGCTAACTGAATATAAAATTATT 420 
17978           ATACACTCTGAGAATAAGAAGATCTTGCTTAATCTGACGCTGACTGAATATAAAATTATT 420 
                **** *** ***** ************************** ****************** 
 
AB031           TCATTCATGATTGACCAGCCTCATAAAGTTTTTACGCGTGGAGAACTTATGAATCACTGC 480 
17978           TCATTCATGATTGATCAGCCTCATAAAGTTTTTACGCGCGGAGAGCTTATGAATCACTGC 480 
                ************** *********************** ***** *************** 
 
AB031           ATGAATGATAGCGATGCACTAGAGCGAACCGTAGATAGCCATGTGAGTAAGCTAAGAAAA 540 
17978           ATGAATGATAGCGATGCACTAGAGCGAACCGTAGATAGCCATGTAAGTAAGCTGAGAAAA 540 
                ******************************************** ******** ****** 
 
AB031           AAACTAGAAGAACAAGGCATATTTCAAATGTTAGTTAATGTGCGTGGCGTGGGATATAGA 600 
17978           AAACTAGAAGAACAAGGCATATTTCAAATGTTAATTAATGTGCGTGGCGTGGGATATAGG 600 
                ********************************* *************************  
 
AB031           CTAGATAATCCCGTAGCTATAAAAGATGATGCCTAATTGGTTGGTCGGGTGAAACTATAT 660 
17978           CTAGATAATCCCCTAGCTGTAAAAGATGACGCCTAA------------------------ 636 
                ************ ***** ********** ******                         
 
AB031           ATAAGTGCACTACAGTTAGAAAATGGAGAGCTTTTACTCGTCGTTTCTCCTCAGTTTAAT 720 
17978           ------------------------------------------------------------ 
                                                                             
 
AB031           GCCAATGCTATTCAGGATTATGCATTACGCTGGGAAATTGAAACCTTATTCAGTTGTCTC 780 
17978           ------------------------------------------------------------ 
                                                                             
 
AB031           AAAGGACGCGGGTTTAATCTTGAAAATACGCGCTTGACAGACCCTAGACGAGTGAAAAAA 840 
17978           ------------------------------------------------------------ 




AB031           TTGATTGCGGTGTTAGCTATAAGCTTCTGTTGGTGTTACTTAACGGGTGAATGGCAACAT 900 
17978           ------------------------------------------------------------ 
                                                                             
 
AB031           AATCAAAAAAAAGCGATAAAAATAAAGAAGCATGGACGACTCTCAATGAGTTTATTTCGC 960 
17978           ------------------------------------------------------------ 
                                                                             
 
AB031           TATGGTTTAGACTATGTTCAAATGGCGATTCAGCGTTTAATTGGTTTTGGGAAAAAAGAA 1020 
17978           ------------------------------------------------------------ 
                                                                             
 
AB031           GAGTTTAAGGAAATTTTGGCAATTTTAAGAAAGCAGAATCCTGATAGGATAAGGGTTCTG 1080 
17978           ------------------------------------------------------------ 
                                                                             
 
AB031           TGATTGGTTGGTCGGGTGAAACTATATATAAGTGCACTACAGTTAGAAAATGGAGAGCTT 1140 
17978           ------------------------------------------------------------ 
                                                                             
 
AB031           TTACTCGTCGTTTCTCCTCAGTTTAATGCCAATGCTATTCAGGATTATGCATTACGCTGG 1200 
17978           ------------------------------------------------------------ 
                                                                             
 
AB031           GAAATTGAAACCTTATTCAGTTGTCTCAAAGGACGCGGGTTTAATCTTGAAAATACGCGC 1260 
17978           ------------------------------------------------------------ 
                                                                             
 
AB031           TTGACAGACCCTAGACGAGTGAAAAAATTGATTGCGGTGTTAGCTATAAGCTTCTGTTGG 1320 
17978           ------------------------------------------------------------ 
                                                                             
 
AB031           TGTTACTTAACGGGTGAATGGCAACATAATCAAAAAAAAGCGATAAAAATAAAGAAGCAT 1380 
17978           ------------------------------------------------------------ 
                                                                             
 
AB031           GGACGACTCTCAATGAGTTTATTTCGCTATGGTTTAGACTATGTTCAAATGGCGATTCAG 1440 
17978           ------------------------------------------------------------ 
                                                                             
 
AB031           CGTTTAATTGGTTTTGGGAAAAAAGAAGAGTTTAAGGAAATTTTGGCAATTTTAAGAAAG 1500 
17978           ------------------------------------------------------------ 
                                                                             
 
AB031           CAGAATCCTGATAGGATAAGGGTTCTGTGAATGCGCCTCGCAAAGCGTTTTATTGTGCCA 1560 
17978           ------------------------------ATGCGCCTCGCAAAGCGTTTTATTGTGCCA 666 
                                              ****************************** 
 
AB031           ATTAACTTCTTAGCCGAAGCAGCAAAAAAAATTAGTCACGGCGACCTCTCTGCTAGAGCT 1620 
17978           ATTAACTTCTTAGCCGAAGCAGCAAAAAAAATTAGTCACGGCGACCTCTCTGCTAGAGCT 726 
                ************************************************************ 
 
AB031           TACGATAACCGAATTCACTCCGCCGAAATGTCGGAGCTTTTATATAATTTTAATGATATG 1680 
17978           TACGATAACCGAATTCACTCCGCCGAAATGTCGGAGCTTTTATATAATTTTAATGATATG 786 
                ************************************************************ 
 
AB031           GCTCAAAAGCTAGAGGTTTCCGTTAAAAATGCGCAGGTTTGGAATGCAGCCATCGCACAT 1740 
17978           GCTCAAAAGCTAGAGGTTTCCGTTAAAAATGCGCAGGTTTGGAATGCAGCCATCGCACAT 846 
                ************************************************************ 
 
AB031           GAGTTAAGAACGCCTATAACGATATTACAAGGTCGTTTACAGGGAATTATTGATGGCGTT 1800 
17978           GAGTTAAGAACGCCTATAACGATATTACAAGGTCGTTTACAGGGAATTATTGATGGCGTT 906 




AB031           TTTAAACTTGATGAAGTTCTATTTAAAAGTCTTTTAAATCAAGTTGAAGGTTTATCTCAC 1860 
17978           TTTAAACTTGATGAAGTTCTATTTAAAAGTCTTTTAAATCAAGTTGAAGGTTTATCTCAC 966 
                ************************************************************ 
 
AB031           TTAGTCGAAGACTTACGGACTTTAAGCTTAGTAGAGAACCAGCAACTCCGGTTAAATTAT 1920 
17978           TTAGTCGAAGACTTACGGACTTTAAGCTTAGTAGAGAACCAGCAACTCCGGTTAAATTAT 1026 
                ************************************************************ 
 
AB031           GAATTGTTTGACTTTAAGGCGGTAGTTGAAAAAGTTCTTAAAGCATTTGAAGATCGTTTG 1980 
17978           GAATTGTTTGACTTTAAGGCGGTAGTTGAAAAAGTTCTTAAAGCATTTGAAGATCGTTTG 1086 
                ************************************************************ 
 
AB031           GATCAAGCTAAGCTAGTACCAGAACTTGACCTAACGTCCACTCCTGTATATTGCGACCGC 2040 
17978           GATCAAGCTAAGCTAGTACCAGAACTTGACCTAACGTCCACTCCTGTATATTGCGACCGC 1146 
                ************************************************************ 
 
AB031           CGTCGTATTGAGCAAGTTTTAATTGCTTTAATTGATAATGCGATTCGCTATTCAAATGCA 2100 
17978           CGTCGTATTGAGCAAGTTTTAATTGCTTTAATTGATAATGCGATTCGCTATTCAAATGCA 1206 
                ************************************************************ 
 
AB031           GGCAAACTTAAAATTTCCTCGGAAGTGGTATCACAAAACTGGATATTAAAAATTGAGGAT 2160 
17978           GGCAAACTTAAAATTTCCTCGGAAGTGGTATCACAAAACTGGATATTAAAAATTGAGGAT 1266 
                ************************************************************ 
 
AB031           GAAGGCCCTGGCATTGCAACCGAGTTCCAAGACGATTTATATAAGCCTTTCTTTAGATTA 2220 
17978           GAAGGCCCTGGCATTGCAACCGAGTTCCAAGACGATTTATATAAGCCTTTCTTTAGATTA 1326 
                ************************************************************ 
 
AB031           GAAGAATCAAGGAATAAAGAATTTGGCGGCACAGGTTTAGGTCTTGCTGTTGTACATGCA 2280 
17978           GAAGAATCAAGGAATAAAGAATTTGGCGGCACAGGTTTAGGTCTTGCTGTTGTACATGCA 1386 
                ************************************************************ 
 
AB031           ATTATTGTGGCACTGAAAGGTACTATTCAATATAGCAACCAAGGCTCGAAAAGTGTTTTC 2340 
17978           ATTATTGTGGCACTGAAAGGTACTATTCAATATAGCAACCAAGGCTCGAAAAGTGTTTTC 1446 
                ************************************************************ 
 
AB031           ACCATAAAAATTTCTATGGGTCATGAAGAAATAGGGTAA 2379 
17978           ACCATAAAAATTTCTATGGGTCATGAAGAAATAGGGTAA 1485 
                *************************************** 
 
